University of South Florida

Scholar Commons
Graduate Theses and Dissertations

Graduate School

2006

Occupancy and function of the hepatic HMGCoA reductase promoter
William Raymond Lagor
University of South Florida

Follow this and additional works at: http://scholarcommons.usf.edu/etd
Part of the American Studies Commons
Scholar Commons Citation
Lagor, William Raymond, "Occupancy and function of the hepatic HMG-CoA reductase promoter" (2006). Graduate Theses and
Dissertations.
http://scholarcommons.usf.edu/etd/2596

This Dissertation is brought to you for free and open access by the Graduate School at Scholar Commons. It has been accepted for inclusion in
Graduate Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please contact
scholarcommons@usf.edu.

Occupancy and Function of the Hepatic HMG-CoA Reductase Promoter

by

William Raymond Lagor

A dissertation submitted in partial fulfillment
of the requirements for the degree of
Doctor of Philosophy
Department of Biochemistry and Molecular Biology
College of Medicine
University of South Florida

Major Professor: Gene C. Ness, Ph.D.
George Blanck, Ph.D.
Kenneth Wright, Ph.D.
Ronald K. Keller, Ph.D.,
Larry P. Solomonson, Ph.D.
Richard Hanson, Ph.D.
Date of Approval:
October 23, 2006
Keywords: In vivo footprinting, in vivo electroporation, insulin, cholesterol,
lovastatin, rat, transcription, liver
© Copyright 2006, William Raymond Lagor

ACKNOWLEDGEMENTS

I sincerely thank Dr. Gene C. Ness for his expert guidance, and financial
support of the research contained in this dissertation. This work would not have
been possible without his friendship, remarkable patience, and steadfast
encouragement. Considerable credit should be given to Eric D. deGroh, who
cloned the HMGR promoter-luciferase plasmids (-325, -228, -176, -123, and -58)
used in this work. This greatly accelerated our progress, and I sincerely thank
him for his effort. I am also grateful to Dr. Aaron Osborne for instruction in
molecular biology, Dr. Dayami Lopez for help with nuclear run-on assays, Dr.
Kenneth Wright, Jenny Wu and Sophie Bolick for advice on in vivo footprinting,
Dr. Keller for constructive criticism and scientific discussion, and Dr. Heller for
his expertise and technical assistance with the in vivo electroporation studies.
Lindsey Jackson, Brittany Doupnik, Reed Holland, Mohammad Hassanyer,
Nicolle Rodriguez, Jose Abisambra, and Dr. Veronica Pollock all contributed to
this research as members of our laboratory team. I also thank my mother, father,
brothers, sisters, and extended family for their unwavering support. I am
particularly grateful to my beautiful wife Jamie, who is my true inspiration.

TABLE OF CONTENTS

LIST OF TABLES

iv

LIST OF FIGURES

v

LIST OFABBREVIATIONS

vii

ABSTRACT

x

INTRODUCTION

1

MATERIALS AND METHODS

21

Plasmids

21

Growth of Bacteria and Isolation of Plasmid DNA

24

Animals

25

Nuclei Isolation

25

Nuclear run-on assay

26

Serum Cholesterol and Glucose

27

Cell Culture

27

DMS treatment of H4IIE cells

29

DMS treatment of rat liver nuclei

29
i

DMS treatment of rat liver

30

DNA extraction

30

Preparation of control DNA and piperidine treatment

32

Ligation-Mediated PCR

33

Identification of protections and enhancements

36

Compilation of in vivo footprinting data

37

Nuclear extract

37

EMSA

38

Transient transfections

39

Chromatin preparation from rat liver

40

Chromatin Immunoprecipitation assays

41

Surgery

44

Electroporation

44

Luciferase Assays

45

Treatment of luciferase data

45

Isolation of Microsomes

47

Western Blotting

47

RNA Isolation and cDNA synthesis

48

Real-Time PCR

49

RESULTS

50

Effect of diabetes and insulin on
HMGR transcription in the liver

51
ii

Effects of insulin on HMGR mRNA levels, serum
cholesterol, and serum glucose with time.

53

In vivo footprinting of the HMGR promoter in H4IIE cells

56

Footprinting of the HMGR promoter from rat liver nuclei

59

In vivo footprinting of the HMGR promoter in rat liver

61

In vitro identification of transcription factors binding
to the footprinted regions of the HMGR promoter

69

Chromatin immunoprecipitation of CREB-1 bound
to the HMGR promoter

75

Effect of the -70/-65 NF-Y site on transcription in
H4IIE cells

77

HMGR promoter function in normal rats

80

Importance of the -70/-65 NF-Y site in driving
transcription in the liver

83

Mapping of HMGR promoter sterol response
by in vivo electroporation

86

The effect of lovastatin and cholesterol feeding
on HMGR expression

87

DISCUSSSION

89

REFERENCES

103

APPENDIX

116

ABOUT THE AUTHOR

End Page

iii

LIST OF TABLES

Table 1

Primer sequences used in experiments

23

Table 2

DNA oligos sequences used as probes
in EMSA experiments

40

iv

LIST OF FIGURES

Fig. 1

The SREBP pathway

10

Fig. 2

Sequence of the rat HMG-CoA reductase promoter

17

Fig. 3

Overview of in vivo genomic footprinting

29

Fig. 4

Overview of in vivo electroporation

44

Fig. 5.

Measurement of HMG-CoA reductase transcription
in normal and diabetic rats by nuclear run-on

52

Time course of HMG-CoA reductase mRNA
activation by insulin

54

In vivo footprinting of the HMG-CoA reductase
promoter in H4IIE cells

57

Footprinting of the HMG-CoA reductase promoter
from rat liver nuclei

60

In vivo footprint of the hepatic HMGR promoter,
bottom strand

62

In vivo footprint of the hepatic HMGR promoter,
top strand

64

In vivo footprinting of the HMGR promoter in
rats fed lovastatin or cholesterol

66

Summary of in vivo DMS reactivity for the hepatic
HMG-CoA reductase promoter

68

EMSA analysis of footprinted regions of the
HMG-CoA reductase promoter

70

EMSA analysis of the promoter region from -152 to -119

71

Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12
Fig. 13
Fig. 14

v

Fig. 15

EMSA analysis of Sp1-like factor binding
to the -142/-119 region

73

Fig. 16

EMSA analysis of the CRE and the -70/-65 NF-Y site

74

Fig. 17

CREB is bound to the HMGR promoter in live animals

76

Fig. 18

Effect of mutating the proximal NF-Y site on
transcription in H4IIE cells

78

Schematic of HMG-CoA reductase
promoter- luciferase constructs

79

Functional mapping of the HMGR promoter
in the livers of normal rats

81

Effect of mutating the proximal NF-Y site on
HMG-CoA reductase promoter activity in live animals

84

Response of the hepatic HMG-CoA reductase promoter
to lovastatin or cholesterol feeding

87

Effect of lovastatin or cholesterol feeding on
HMG-CoA reductase immunoreactive protein levels

88

Effect of lovastatin or cholesterol feeding on
HMGR mRNA levels

89

Effect of lovastatin or cholesterol feeding on
HMG-CoA synthase mRNA levels

90

Model of the HMGR promoter in normal
and diabetic rat liver

96

Fig. 19
Fig. 20
Fig. 21
Fig. 22
Fig. 23
Fig. 24
Fig. 25
Fig. 26.

vi

LIST OF ABBREVIATIONS

ABCA1

ATP binding cassette transporter A 1

ABCG1

ATP binding cassette transporter G 1

ABCG5/8

ATP binding cassette transporters G 1 and G8

ALLN

N-acetyl-leucyl-leucyl-norleucynal

Apo-

apolipoprotein

ATP

adenosine triphosphate

BCA

bicinchoninic acid

BLUE

bluescript

bp

base pairs

BSA

bovine serum albumin

CAT

catalase

CETP

cholesteryl ester transfer protein

ChIP

chromatin immunoprecipitation

CHO

Chinese hamster ovary cells

cm

centimeter

CRE

cyclic AMP response element

CREB-1

cyclic AMP response element binding protein

CVD

cardiovascular disease
vii

DMS

dimethyl sulfate

dpm

detections per minute

DTT

dithiolthreitol

ECL

enhanced chemiluminescence

EDTA

ethylenediaminetetraacetic acid

EGTA

ethylene glycol-bis [β-aminomethyl-etherN,N,N’,N’tetraacetic acid]

EMEM

Eagles modification of essential media

EMSA

electrophoretic mobility shift assay

ER

endoplasmic reticulum

HCS

HMG-CoA Synthase

HMG-CoA

3-hydroxy-3-methylglutaryl coenzyme A

HMGR

HMG-CoA reductase

HDL

high density lipoprotein

HEPES

N-[2-hydroxyethyl]piperazine-N’-[2ethanesulfonic acid]

HPLC

high performance liquid chromatography

IDL

intermediate density lipoprotein

Insig

insulin induced gene product

LCAT

lecithin: cholesterol acyl transferase

LDL

low density lipoprotein

LDLR

low density lipoprotein receptor

LRP

LDL receptor related protein

LRH-1/FTF

liver receptor homologue-1 / fetoprotein transcription factor
viii

mRNA

messenger ribonucleic acid

PCR

polymerase chain reaction

PPAR-alpha

peroxisome proliferator activator receptor- alpha

rATP

ribosyl adenosine triphosphate

SRE

sterol response element

NF-Y

nuclear factor- Y

NPCL1

Niemann Pick C like protein 1

Ox-LDL

oxidized LDL

PBS

phosphate buffered saline

PMSF

phenylmethylsulfonyl fluoride

RT-PCR

reverse transcriptase polymerase chain reaction

SCAP

SREBP cleavage accessory protein

SDS

sodium dodecyl sulfate

SRB-I

scavenger receptor B one

SRE

sterol response element

SREBP

sterol response element binding protein

TB-β1

thyroid receptor beta 1

TBE

Tris borate EDTA

TEMED

N,N,N’,N’-Tetramethylethylenediamine

Tris

Tris [hydroxymethyl]aminomethanehydrochloride

tRNA

transfer- ribonucleic acid

VLDL

very low density lipoprotein

ix

OCCUPANCY AND FUNCTION OF THE HEPATIC
HMG-COA REDUCTASE PROMOTER
William Raymond Lagor
ABSTRACT

HMG-CoA reductase (HMGR) catalyzes the rate controlling step in
cholesterol production. This enzyme is highly expressed in the liver where it is
subject to extensive hormonal and dietary regulation. This study was undertaken
to examine the occupancy and function of the hepatic HMGR promoter in regards
to insulin and sterol regulation. HMGR protein and mRNA are substantially
decreased in diabetic animals and rapidly restored by administration of insulin.
Nuclear run-on assays revealed that HMGR transcription was substantially
reduced in the diabetic rats, and fully restored within two hours after insulin
treatment. In vivo footprinting revealed several areas of protein binding as shown
by dimethyl sulfate protection or enhancement. The CRE was heavily protected
in all conditions - including diabetes, cholesterol feeding, or statin treatment.
Striking enhancements in footprints from diabetic animals were observed at -142
and at -161 (in the SRE). Protections at a newly identified NF-Y site at -70/-71
were seen in normal animals, and not in diabetics. This proximal NF-Y site was
x

found to be required for efficient HMGR transcription. CREB-1 was able to bind
the HMGR CRE in vitro, and to the promoter in vivo. The data supports an
essential role for CREB in transcription of hepatic HMGR, and identifies at least
two sites where in vivo occupancy is regulated by insulin. The technique of in
vivo electroporation was utilized to perform the first functional analysis of the
HMGR promoter in live animals. Analysis of a series of deletion constructs
showed that deletion of the region containing the cyclic AMP response element
(CRE) at -104 to -96 and the newly identified NF-Y site at -70 resulted in marked
reduction of promoter activity. Possible sterol regulation of the promoter was
investigated by raising tissue cholesterol levels by feeding cholesterol, or by
inhibiting cholesterol synthesis with a statin (lovastatin). It was found that HMGR
promoter constructs responded to lovastatin, in agreement with previous findings
in cultured cells. This work sheds light on the regulation of the HMGR promoter in
the liver, whose expression is a key determinant of serum cholesterol levels- a
major risk factor for cardiovascular disease.

xi

INTRODUCTION

Cholesterol is an essential component of mammalian cells. In addition to
its role in maintaining membrane structure, it is also required for the production of
bile acids, steroid hormones, (1) and in at least one case, serves as a posttranslational modification (2). Newly synthesized cholesterol is essential for
development of tissues as well as proper organ function. The cell expends a
great deal of energy in the production of cholesterol. In contrast to fatty acids,
proteins, and carbohydrates, there is no system for the regeneration of energy
from the cholesterol molecule, or breakdown of its carbon skeleton. Because of
this, the body has evolved an intricate system to ensure that this valuable
molecule is not lost. Cholesterol is packaged into lipoprotein particles in the
bloodstream and is then carried throughout the body. Maintaining an ample
supply of cholesterol is crucial as even minor defects can have drastic
consequences (3). The great irony is that the same lipoprotein particles which
nourish the cells with cholesterol and other lipids, can also make a significant
contribution to human disease.

Elevated serum cholesterol is a major risk factor for cardiovascular
disease (CVD) (4), which continues to be the primary cause of death in the US
1

and most developed countries. While there is still much to learn about the role of
cholesterol in the pathogenesis of CVD, a great deal is already known. There are
two sources of cholesterol- dietary cholesterol, and newly synthesized
cholesterol. Dietary cholesterol enters the body through the intestine. This
process is dependent on Niemann-Pick C1-like 1 protein (NPCL1) (5), a putative
cholesterol transporter. Along with fatty acids and triglycerides, the newly
absorbed cholesterol is packaged into chylomicrons and enters the bloodstream.
Chylomicrons are acted upon by lipoprotein lipase which cleaves triglycerides
thereby liberating free fatty acids from the particle. The resulting chylomicron
remnants are taken up by the LDL receptor related protein (LRP) in the liver (6).
In this organ, dietary cholesterol then merges with the newly synthesized
cholesterol pool. A portion of this cholesterol will be converted to bile acids and
exit through the bile ducts. The bile acids enter the intestine where they function
as detergents to solubilize dietary fat. The majority of the bile acid pool is
recycled back to the liver, but a fraction of it is excreted (7). The ATP binding
cassette G5 and G8 transporters (ABCG5/8) also function to remove part of the
cholesterol pool from the liver into the bile (8). In the intestine, ABCG5 and G8
are the primary proteins responsible for removal of plant sterols from the body,
and are important players in the efflux of unmodified cholesterol.

Cholesterol esters, cholesterol, and triglycerides are packaged into very
low density lipoprotein particles (VLDL) in the liver and secreted into the
bloodstream. The VLDL particle provides the peripheral tissues with a valuable
2

source of cholesterol, as well as energy in the form of triglycerides. The VLDL
particle is large in size, and has apolipoproteins B-100, C-I, C-II, C-III, and E as
its primary protein constituents (9). These VLDL particles carry triglycerides to
the muscle and heart, which have a particular receptor that is specific for this
lipoprotein. VLDL has an abundance of apolipoprotein C-II which prevents
efficient interaction with the low density lipoprotein receptor. Circulating VLDL is
a target of lipoprotein lipase. This enzyme cleaves triglycerides into free fatty
acids which then enter peripheral tissue, or bind to albumin to remain in the
bloodstream. After interacting with lipoprotein lipase, the particle now contains a
larger percentage of cholesterol, and is reclassified as an intermediate density
lipoprotein (IDL) particle. IDL particles have lost some of their apolipoprotein C
component, and are smaller in size than VLDL. These particles have
apolipoprotein E (Apo E), the high affinity ligand for the LDL receptor. For this
reason, IDL efficiently binds to the LDL receptor, and is taken into the liver.
Without a doubt, this is the primary route of cholesterol clearance from the blood.
Defects in either the LDL receptor or apoE genes, have devastating
consequences for cholesterol balance. A defect in LDLR is the basis for familial
hypercholesterolemia type II, a disease in which subjects may have serum
cholesterol levels in excess of 400 mg / dl, and often die from coronary artery
disease in their twenties to fifties (10).

When the amount of total cholesterol in the blood exceeds the LDL
receptor’s clearance capacity, low density lipoprotein particles (LDL) will
3

accumulate. LDL particles form as a result of the action of lipoprotein lipase on
circulating IDL particles. Along with the loss of triglyceride mass, there is also a
corresponding loss of Apo E. This leaves the LDL particle with only
apolipoprotein B-100 (Apo B-100) as its primary protein ligand. The LDL particle
is then less amenable to internalization by the LDL receptor. Circulating LDL not
cleared by the LDLR are taken up by the scavenger receptor (SRB-I). These
receptors are present in all cell types, including macrophages. LDL cholesterol
tends to linger in the bloodstream longer than other lipoprotein particles. During
this time, it is subject to oxidation by free radicals, as well as reactive oxygen and
nitrogen species. The resulting oxidized LDL (ox-LDL) are taken up by
macrophages via the scavenger receptor. After ingesting more oxidized LDL,
macrophages turn into foam cells that deposit themselves in the artery wall. The
foam cells eventually die and lead to further inflammation, exacerbating the
problem (11). At this stage, large extracellular deposits of cholesterol and lipid
begin to stack up and form atherosclerotic plaques. Plaque formation is a
progressive process that continues throughout life, as long as LDL cholesterol
levels are sufficiently elevated. Over time the plaques can rupture, allowing clots
to occlude blood vessels, leading to peripheral artery disease, stroke, and heart
failure.

Reverse cholesterol transport is a key determinant in the rate of
atherosclerotic plaque formation (12). Macrophages that have infiltrated the
endothelium can also get rid of excess cholesterol. This is thought to happen
4

primarily through the actions of ATP binding cassette transporter A1 (ABCA1),
and ATP binding cassette transporter G-1 (ABCG1). These proteins can
transport unesterified cholesterol from the macrophages to lipid-poor nascent
HDL particles in the serum. The nascent HDL particles have apolipoprotein A-1
as their protein component. With the action of Lecithin: Cholesterol Acyl
Transferase (LCAT), the free cholesterol is then converted into cholesterol esters,
and is sent to the core of the particle. This results in the formation of the high
density lipoprotein particles- HDL2 and HDL3, which are rich in protein and
phospholipids. These HDL particles can then be taken up by SR-BI in the liver
and eliminated. HDL particles can also exchange lipids with circulating VLDL and
IDL. Cholesterol Ester Transfer Protein (CETP) brings cholesterol esters from the
HDL particle to the VLDL/IDL particle. This represents a significant action of the
HDL cholesterol. VLDL particles will eventually become IDL, and direct their
cholesterol load to the liver via the LDL receptor. Low HDL levels are an
independent risk factor for CVD. For these reasons, high HDL levels are
desirable, as they can favorably shift the equilibrium from cholesterol deposition
to efflux.

While cholesterol absorption is a major player in the development of CVD,
the role of cholesterol synthesis is even more important. In human beings, sterol
synthesis accounts for between 60 and 80% of the total cholesterol pool (1). Due
to obvious technological and ethical barriers, it is still unclear what contribution
each tissue makes to whole body cholesterol synthesis in humans (13). Early
5

measurements of 14C- acetate incorporation showed the liver and intestine were
responsible for the bulk of cholesterol synthesis in rats (14), and squirrel
monkeys (15). In these animals, only liver cholesterol synthesis was affected by
fasting and refeeding, or feedback inhibited by dietary cholesterol. This contrasts
with experiments with 1-14C- octanoate labeling in rabbits where the liver made
only a minor contribution to cholesterol synthesis (16). Rabbits are very
susceptible to dietary cholesterol. Interestingly, rabbits had feedback inhibition by
dietary cholesterol in all the tissues examined. It was later discovered that
labeling with 14C- acetate or 1-14C- octanoate may in fact misrepresent the true
rates of sterol synthesis due to variations in the acetate pool (17). The
development of a tritiated water-based assay greatly improved absolute
measurements of sterol synthesis (18,19). Experiments with 3H- H2O showed
that over 50% of cholesterol synthesis occurs in the livers of male Sprague
Dawley rats (20). A more systematic study using rats, monkeys, hamsters,
rabbits and guinea pigs, was also performed using this method. It was
discovered that in the rat, monkey and hamster, the liver contained more newly
synthesized cholesterol than any other organ (21), in contrast to rabbits and
guinea pigs which had less total synthesis.

More than any other organ, the liver plays a critical role in the control of
cholesterol balance. Virtually all the cholesterol that enters or leaves the body
passes through the liver. Dietary cholesterol is brought from the intestine to the
liver where it mixes with newly synthesized cholesterol. The cholesterol can then
6

be packaged into VLDL particles and secreted into the bloodstream. This particle
provides a source of triglycerides and cholesterol for peripheral tissues and is the
precursor of IDL and LDL. The liver guards against excess serum cholesterol
through the action of the LDL receptor (LDLR) (22). The LDL receptor removes
IDL, and to a lesser extent LDL particles from the bloodstream. Once in the liver,
the excess cholesterol can be converted to bile acids, esterified or directly
effluxed as unmodified cholesterol. This clearance from the bile ducts into the gut
is the primary route of cholesterol elimination from the body. The liver integrates
all of these processes through a series of complex regulatory networks. At the
center of this is 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR), the
rate-controlling enzyme in cholesterol biosynthesis.

HMGR is an enzyme that functions as a dimer in the endoplasmic
reticulum. Each monomer consists of eight membrane spanning domains as well
as a cytoplasmic catalytic domain (23). HMGR utilizes two reducing equivalents
of NADPH to convert 3-hydroxy-3-methylgutaryl coenzyme A to mevalonate. This
is the rate-limiting reaction in the biosynthesis of cholesterol and a critical control
point for regulation. In addition to cholesterol, mevalonate is also the precursor of
important non-sterol products including isopentenyl tRNA, heme A, ubiquinone,
dolichol, farnesyl pyrophosphate, and geranylgeranyl pyrophosphate. Since cells
cannot survive without a source of mevalonate or cholesterol, an elaborate
regulatory network has evolved to ensure adequate rates of synthesis. Equally
intricate mechanisms guard against over expression of HMGR, which would lead
7

to the toxic accumulation of excess cholesterol. These mechanisms act at
transcriptional, as well as several posttranscriptional levels to fine tune HMGR
activity; this phenomenon has been termed multivalent regulation (24).

HMGR is highly expressed in the liver, the primary site of regulatable
cholesterol synthesis. Hepatic HMGR activity is affected by cholesterol, insulin,
thyroid hormone, bile acids, fasting and refeeding, and also varies diurnally (5).
Like many other enzymes, HMGR is subject to phosphorylation (25,26). It has
been shown that HMGR has less catalytic activity when phosphorylated.
However the phosphorylation status does not vary under most physiological
conditions (27), and therefore does not play a significant regulatory role. In
contrast to many other enzymes, HMGR activity is controlled almost exclusively
by changes in expression.

Cholesterol has, without a doubt, the most important influence on HMGR
protein levels. Feedback inhibition of cholesterol biosynthesis was first observed
by Schoenheimer and Breusch in 1933 when they noticed that mice produced
more cholesterol on a low cholesterol diet. This accumulation stopped when
placed on a cholesterol rich diet (28). Years later, this observation was confirmed
with 14C- acetate labeling in dogs (29). Liscum and others discovered that rats
expressed 33 times more HMGR when fed a diet containing colestipol (a bile
acid binding resin) and mevinolin (an inhibitor of HMGR) than those fed a chow
diet. It was found that protein and mRNA levels were both significantly reduced
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by cholesterol feeding (30) in these colestipol and mevinolin fed animals. This
was attributed to an inhibitory effect of cholesterol on HMGR transcription. Since
that time, a great deal of work has been done in cultured cells to elucidate the
exact mechanisms of this feedback inhibition. This ultimately led to the discovery
of the SREBP pathway (31).

In cultured cells, HMGR transcription is repressed by decreased binding of
sterol regulatory element binding proteins (SREBPs) to the promoter (32).
SREBPs are transcription factors that are synthesized as membrane bound
precursors in the endoplasmic reticulum (33). SREBPs normally associate with
SREBP cleavage-activating protein (SCAP) which forms a tertiary complex with
insulin induced gene product (Insig) protein in the presence of sterols (34). SCAP
contains a YIYF motif that has been identified as a sterol sensing domain.
Binding of sterols to this domain induces a conformational change in SCAP,
causing it to associate tightly with Insig. Insig can be thought of as an ERretention protein. It serves as an anchor to keep the SREBP/SCAP complex
pinned in the ER when sufficient sterols are present. When sterol levels fall, the
SCAP/SREBP complex dissociates from Insig. SCAP then escorts SREBPs to
the Golgi where they are cleaved by two proteases to liberate their mature, active
N-terminal domains (35). These N-terminal domains are basic helix-loop-helixleucine-zipper transcription factors which when released, migrate into the
nucleus, dimerize, and bind to the SREs of target genes to activate transcription
(Figure 1). There are three SREBP isoforms: 1a, 1c, and 2. SREBP-1a, and 1c
9

are splice variants that are involved in fatty acid metabolism (36) while SREBP-2
is specific for genes involved in cholesterol metabolism (37).

SCAP

SREBP

Insig

Insig

Cytoplasm

ER

SREBP-NH2
Sterols
SCAP

SREBP

Nucleus

SRE

Golgi

FIGURE 1. The SREBP pathway. SREBPs are first synthesized as membrane
bound precursors in the ER. When sterol levels are sufficient, they form a tertiary
complex with SCAP and Insig. When sterol levels fall sufficiently low, SCAP
undergoes a conformational change and dissociates from Insig. The
SCAP/SREBP complex is then escorted to the Golgi where SREBP is then acted
on by two proteases (not shown). The SREBP NH2- terminal domains dimerize
and translocate to the nucleus. Once inside, they bind to the SREs of target
genes to activate transcription.
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In the liver, cholesterol decreases HMGR protein primarily by a
posttranscriptional mechanism. Feeding rats a diet containing 2% cholesterol
dramatically reduces HMGR protein levels, yet has little to no effect on mRNA
levels (38). This is in contrast with previous findings in animals fed a basal diet of
colestipol and mevinolin (30). It was found that under normal physiological
circumstances, cholesterol does little to repress transcription in the liver. The
transcriptional effects are typically observed only in the presence of cholesterol
lowering agents (39). The exact mechanism for feedback inhibition by cholesterol
in rat liver has not been determined. One factor appears to be slowing of
translation of the HMGR message due to dietary cholesterol (27,40). RNA from
cholesterol fed animals was found to be associated almost exclusively with the
inefficiently translating monosome fraction. Dietary cholesterol also inhibited
incorporation of 35S-methionine into HMGR in isolated liver slices. Consistent
with this, there was no change in the half life of the HMGR protein when rats
were treated with cycloheximide to inhibit protein synthesis. At present it is
unclear whether this effect on translation is a direct effect of dietary cholesterol or
the result of the accumulation of an intermediate. In addition, it is unclear whether
the magnitude of this effect is sufficient to account for the total reduction in
HMGR protein.

Other evidence suggests that cholesterol acts by accelerating degradation
of HMGR (41-43). HMGR has a sterol sensing domain (similar to that found in
11

SCAP) that allows it to interact with Insigs (44). Recently, it has been shown that
lanosterol in particular promotes Insig-dependent ubiquitination and degradation
of HMGR in cultured cells (45). This occurs through recognition of the
HMGR/Insig complex by gp78, a membrane-bound ubiquitin ligase. Gp78 in turn
binds to VCP, an ATPase involved in recognition and degradation of proteins in
the ER. HMGR is then sent to the proteasome to be degraded. Currently, there is
no direct evidence that this is the regulatory mechanism at work in the liver.
However, the liver-specific Insig knockout mouse has now been generated (46).
These animals have constitutive processing of SREBPs because the
SCAP/SREBP complex cannot be retained in the ER. HMGR mRNA levels were
elevated in these mice as expected, but protein levels were disproportionately
higher. An overwhelming amount of HMGR protein was present, and this affect
was attributed to the inability of Insig to turnover HMGR. Further experiments are
needed to actually measure the rates of HMGR protein translation and
degradation in these Insig deficient animals.

Dietary intake of cholesterol can have a major impact on liver cholesterol
levels. Conversely, there are several drugs currently in use that can markedly
reduce liver and serum cholesterol levels. Ezetimibe, an inhibitor of cholesterol
absorption in the intestine (47), is effective at lowering serum cholesterol levels in
humans (48). Treatment with ezetimibe results in restoration of HMGR protein
levels to normal in diabetic rats, even when fed a cholesterol-rich diet (49).
Another class of drugs, the “statins” act by inhibiting HMG-CoA reductase activity,
12

thus slowing cholesterol synthesis in the liver. Millions of people worldwide are
currently taking a statin. These drugs have been shown to reduce serum
cholesterol levels (50), improve survival rates for those at risk for coronary events
(51), and even reduce the size of atherosclerotic lesions (52). In contrast to
cholesterol feeding, statins cause a transient depletion of intracellular cholesterol
levels. The effectiveness of these drugs is limited by the ability of HMGR to
“bounce back” and compensate for the inhibition of cholesterol synthesis. When
rats are fed a statin, HMGR protein levels may be increased by as much as 700fold (53). This compensation occurs at both transcriptional and
posttranscriptional levels, likely by reversal of the mechanisms affected by
cholesterol feeding. Research into the effects of statins on hepatic HMGR
expression is of critical importance to treatment of cardiovascular disease.

Thyroid hormone levels have a major influence on HMGR expression.
Hypophysectomized and thyroidectomized rats both have very low levels of
HMGR protein. HMGR expression can be restored to normal by administering T3.
In contrast to cholesterol, this effect is entirely accounted for by the increase in
HMGR mRNA levels (54). Thyroid hormone stimulates transcription of the HMGR
gene in the liver about 5-fold based on nuclear run-on assays (55). This effect on
transcription takes about 96 hours to reach it maximum (56). The slow induction
may be due to the synthesis of another thyroid hormone responsive transcription
factor, such as SREBP-2 which is induced transcriptionally by Thyroid Receptor
Beta 1 (TR-β1) (57). Thyroid hormone also stabilizes the HMGR message, by
13

four to six-fold (58,59) . This can be antagonized by the administration of
synthetic glucocorticoids (44), and the exact mechanism is not known. Both of
these effects need further investigation.

HMG-CoA reductase activity varies throughout the day in rodents (60) and
humans (61). Although initially ascribed to alterations in the phosphorylation state
of the enzyme (62), this was later found to be due to corresponding changes in
HMGR mRNA and immunoreactive protein levels (63,64). Curiously, this diurnal
rhythm is lost in PPAR-alpha deficient mice (65). It should be noted that HMGR
expression is at its peak during the first few hours of the dark cycle,
corresponding with the primary feeding time for rats and mice. Indeed, fasting
and refeeding alone have a dramatic effect on HMGR expression that exceeds
the magnitude of the diurnal rhythm. Fasted rats have considerably less HMGR
activity and expression than fed rats (66,67). HMGR reductase levels return to
normal shortly after refeeding. It is therefore likely that changes in food intake
explain the majority of the diurnal variation in HMGR.

Bile acids are modified cholesterol derivatives that emulsify cholesterol,
lipids, and fat soluble vitamins in the intestine. These are secreted into the gut
during feeding. Cholesterol is then needed to replenish the bile acid pool. This
cholesterol is obtained by internalization via the LDL receptor, as well as new
synthesis. This necessitates increased HMGR expression, and may have been a
driving force in the regulation of this gene in mammals. Bile acid feeding has
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been shown to exert a potent suppressive effect on HMGR (68). Conversely,
removal of bile acids by cholestyramine, a bile acid sequesterant, greatly
elevates HMGR protein levels (69). This effect may be due to lowering of liver
cholesterol levels, or alternatively to a more direct effect of bile acids on HMGR
expression (70).

Insulin levels rise during feeding to promote the absorption of serum
glucose, and also to stimulate glycogen and fatty acid synthesis. Conversely,
during periods of fasting, glucagon levels rise to promote gluconeogenesis, fatty
acid oxidation and glycogenolysis. The balance between insulin and glucagon
signaling is a key regulator of many metabolic processes (71). It is not surprising
then that HMGR is also an insulin-regulated gene (72). In this way insulin can
activate HMGR during periods of feeding to provide new cholesterol for the liver
as well as for the replenishment of the bile acid pool. Type I diabetics have lower
rates of cholesterol synthesis and increased absorption of dietary cholesterol (73).
HMG-CoA reductase (HMGR) protein and mRNA levels are both decreased in
streptozotocin-induced diabetic rats, and can be rapidly restored with insulin
treatment (74) suggesting regulation at the transcriptional level. The effect of
insulin on HMGR message levels can be observed even in the presence of
cycloheximide (74). This suggests that the action of insulin is direct, and does not
occur by increased synthesis of the responsible protein(s). Previous experiments
in H4IIE cells (rat hepatoma), showed that the proximal reductase promoter could
be activated by insulin, at levels greater than or equal to those seen in live
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animals (75). Questions remain as to whether the insulin activation observed in
hepatoma cells mirrors the physiological regulation of the gene.

The HMGR promoter has been well-characterized in cell culture. The
promoter lacks a classical TATA box and CCAAT box found in most other
eukaryotic genes. It is very GC-rich and exhibits 90% identity between the human,
mouse, rat and hamster sequences. The major regulatory elements are highly
conserved between these species. Early work found that the hamster HMG-CoA
reductase gene requires about 300 base pairs of sequence upstream of the
transcription start site for high level expression in HeLa cell extracts (76), and in
mouse L cells (32). Further studies were successful in identifying the sterol
responsive element in the HMGR promoter (77). The HMGR promoter contains a
variant sterol response element (SRE) of the sequence GTGCGGTG (78) which
is a 7/8 bp match to the consensus SRE found in the LDL receptor (79), and
HMG-CoA synthase promoters (80), albeit on the opposite strand of the DNA.
The HMGR promoter can be activated by SREBP-1 and SREBP-2 in cultured
cells, and in transgenic mice overexpressing these proteins (11, 12, 13). The
SREBP-2 knockout mouse is not viable, but the SREBP-1 knockout mice shows
increased HMGR expression, owing to compensation by SREBP-2. Although
SREBP-1c appears to be insulin-responsive at the mRNA level, recent evidence
suggests this factor is more closely tied to lipogenesis than cholesterol
biosynthesis (14-16). SREBP-1a and 1c prefer an E-box binding motif which is
not present in the HMGR promoter, although they have been shown to bind the
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promoter in vitro (81). SREBP-2 binds to the classical SRE motif, and is a potent
activator of the HMG-CoA reductase gene. The HMGR promoter also contains
potential binding sites for NF-Y, Sp1, as well as a functional cyclic AMP response
element (CRE) (82,83). Recently, an LRH-1/FTF site has been identified, that is
proposed to mediate repression by bile acids on the human promoter (70)
(Figure 2).

Rat HMG-CoA reductase promoter
-325
CTGCAGGTCA AATTCTGAGT TCGGGGTACT CCACCCGCGG
LRH-1/FTF
-275
CCCCCGCGCG GGCGGCGTCC GGCAGGCGCC CCCACGGCTC
-225
For. primer reads “C’s” →
AGGAAGGCCG CGATGCTGGG ACCCGACTAG CCATTGGTTG
NF-Y
-175
GGTGAGAGAT GGTGCGGTGC CCGTTCTCCG CCCGGGTGCG
SRE
Sp1-like
-125
GGTTGTTAGG GCGACCGTTC GTGACGTAGG CCGTCAGGCT
CRE
-75
CCGCCGATTG GCTAGGGGAT CGGACGATCC TTCCTTATTG
NF-Y
←Rev. primer reads “G’s”
-25

AATCCCCTGT

GGGGACCAAT

GCTCGGCCGT

AGCAGTGGGC

GAGCAGCCTC
GCGGCCGGTT

GGCGGCCCGG AGCGTGCGTA AGCGCAGTTC CTTCCGCCCT GGTCTCCGTT
TRANSCRIPTION START→
+26
+70
GGCTGGAGAC GGCGGCAGGG CCGGCTTGGT GGCCTCCATT GAGAT

FIGURE 2 Sequence of the rat HMG-CoA reductase promoter. The rat HMGCoA reductase promoter was cloned by PCR and sequenced. The major
transcription factor binding sites are underlined. These include a recently
identified LRH-1/FTF site at -321/-316, an NF-Y site at -204/-189, the sterol
response element (SRE) at -164/+155, and the Cyclic AMP response element
(CRE) at -105/-96. The Sp-1 like site at -147/-135 and the NF-Y site -70/-65 were
first identified in this work. The boldface A denotes the transcription start site.
Locations of the labeling primers for footprinting are indicated by the arrows.
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In regards to insulin regulation of the HMGR promoter, previous work from
our laboratory was performed in H4IIE cells, a rat hepatoma cell line. The
hamster HMG-CoA reductase promoter was evaluated for insulin-responsiveness
by transient transfections of luciferase reporter genes. Addition of 0.1 µM insulin
to these cells resulted in a 10-fold activation of transcription with the full length
promoter construct (-270 to +20). Mutation of the SRE had no effect on insulin
stimulation, while mutation of the CRE abolished the insulin effect. During
subsequent work with the H4IIE cells, it was found that the magnitude and nature
of the response was not very predictable. Passage time, and to a greater extent,
cell density both seemed to affect the insulin response. In many cases, treatment
with insulin caused a noticeable change in the morphology of the cells. H4IIE
cells would lose their squared-off appearance and develop into more of a
spindle-shaped structure. It seems likely that in culture, insulin may cause these
cells to differentiate and lose their hepatocyte character. Insulin is a hormone that
is known to affect both cell growth and viability in culture (84,85). In addition,
numerous tumor cell lines have lost the normal feedback regulation for HMGR
(86,87). Aberrant regulation of HMGR in these cells may confer a selective
advantage to them in terms of growth or viability (88) as cholesterol and other
mevalonate-derived products are indispensable for growth. For these reasons,
there is considerable doubt that the insulin effect observed in H4IIE cells is an
accurate reflection of the in vivo situation in the liver.
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Virtually everything known about the HMGR promoter has been gleaned
from in vitro studies, or transfections in cultured cells. Previous in vitro
footprinting studies of the HMGR promoter provided a wealth of information
about potential transcription factor binding sites (76), but left many unanswered
questions about the in vivo occupancy of these footprinted areas. The only in
vivo footprints of the HMGR promoter have been performed in Jurkat and HepG2
cells. Despite a 1.5 fold response to insulin, the HepG2 cells displayed no
noticeable changes in promoter occupancy (89). To date there has been no work
on the regulation of the HMGR promoter within the physiological framework of
the liver.

To address these questions, we have chosen to examine the occupancy
and function of the HMGR promoter in the liver. Performing these studies in live
animals ensures that our results will reflect the physiological regulation of HMGR,
in the context of the many nutritional and hormonal stimuli that the liver receives.
Toward this end, we have examined the response of the HMGR promoter to two
key stimuli: insulin and sterols. In order to directly examine the occupancy of the
HMGR promoter, we have adapted the in vivo genomic footprinting technique to
isolated liver nuclei as well as fresh liver. To evaluate the function of the
footprinted regions, we have used in vivo electroporation (90,91) to deliver
HMGR promoter-luciferase reporter genes to the livers of live animals. We have
found that diabetes markedly alters the occupancy of the hepatic HMG-CoA
reductase promoter. In addition, we have performed the first functional analysis
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of the hepatic HMGR promoter and observed sterol responsiveness in live
animals.
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MATERIALS AND METHODS

Materials- Materials used in this work were obtained from various suppliers, and
are mentioned under the method section for each particular experiment.
Radioisotopes were obtained from Perkin Elmer. Unless otherwise indicated,
chemicals were from Sigma-Aldrich.

Plasmids- The HMG-CoA reductase promoter was obtained by PCR from rat
genomic DNA. Primers were designed to amplify regions of the HMGR promoter
from -325, -228, -176, -123, and -58 on the 5’ end to a common end extending to
+70 on the 3’ end (see acknowledgements). An additional larger fragment of the
promoter ranging from -770 to +441 was also cloned. Primers for PCR were
designed to introduce an Mlu I site on the 5’ end, and an Xho I site on the 3’end.
The PCR products were then digested and ligated into pGL3 basic. These
plasmids encode the firefly luciferase gene driven by different fragments of the
HMGR promoter. The resulting plasmids are named as follows: -770/+441, -325,
-228, -176, -123, -58 and are referred to as A-F in the text respectively (Figure
19). HMGR promoter-luciferase plasmids based on the -325 plasmid, harboring
point mutations in the -70/-65 NF-Y site, were generated using the Quik Change
kit from Stratagene. Primers for cloning were designed using the rat genome
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reference sequence (Genbank accession no. NW_047617.1) and are listed in
Table I. Clones were initially identified by restriction digestion, and then
confirmed by DNA sequencing at either Retrogen (San Diego) or the Moffitt
Molecular Biology Core Facility (University of South Florida, Tampa FL). Renilla
luciferase plasmids phRL-TK (Thymidine Kinase promoter) and phRL-CMV
(Cytomegalovirus promoter) were from Promega.
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Table I
Primer

Purpose

Direction

Target

Sequence

-770

Cloning

Forward

promoter

GCCGACGCGTGCCAGAAGCAGAAGGTGTAAGCAC

-325

Cloning

Forward

promoter

GCGCACGCGTCTGCAGGTCAAATTCTGAGTTCG

-228

Cloning

Forward

promoter

GCGCACGCGTAATAGGAAGGCCGCGATGCT

-176

Cloning

Forward

promoter

GCGCACGCGTTGGTGAGAGATGGTGCGGT

-123

Cloning

Forward

promoter

GCGCACGCGTTTGTTAGGGCGACCGTTCGTGA

-58

Cloning

Forward

promoter

GCGCACGCGTGATCGGACGATCCTTCCTTATTG

70

Cloning

Reverse

promoter

GCGCCTCGAGATCTCAATGGAGGCCACCAAGC

441

Cloning

Reverse

promoter

GCGCCTCGAGGCCTGTATCTGGCTCTTCTCCAT

NF-Y mut A for

Mutagenesis

Forward

promoter

GAGCAGCCTCCCGCCGATAAGCTAGGGGAT

NF-Y mut A rev

Mutagenesis

Reverse

promoter

CGATCCCCTAGCTTATCGGCGGGAGGCTGCTC

NF-Y mut B for

Mutagenesis

Forward

promoter

GAGCAGCCTCCCGCCGAGGGGCTAGGGGATCG

NF-Y mut B rev

Mutagenesis

Reverse

promoter

CGATCCCCTAGCCCCTCGGCGGGAGGCTGCTC

Footprinting A-1

Footprinting

Extension

promoter

CAATAGGAAGGCCGCGATGC

Footprinting A-2

Footprinting

PCR

promoter

ATGCTGGGACCCGACTAGCCATTG

Footprinting A-3

Footprinting

Label

promoter

ATGCTGGGACCCGACTAGCCATTGGTTG

Footprinting B-1

Footprinting

Extension

promoter

CGGAAGGAACTGCGCTTACG

Footprinting B-2

Footprinting

PCR

promoter

AACCGGCCGCCAATAAGGAAGGATC

Footprinting B-3

Footprinting

Label

promoter

CGGCCGCCAATAAGGAAGGATCGTCCGATC

Long Linker primer

Footprinting

Linker

syn. linker

GCGGTGACCCGGGAGATCTGAATTC

Short liner primer

Footprinting

Linker

syn. linker

GAATTCAGATC

ChIP HMGR for

ChIP

Forward

promoter

CAATAGGAAGGCCGCGATGC

ChIP HMGR rev

ChIP

Reverse

promoter

CGGAAGGAACTGCGCTTACG

ChIP Exon 12 for

ChIP

Forward

Exon 12

GGCGGTCAGTGGTAACTATT

ChIP Exon 12 rev

ChIP

Reverse

Exon 12

GCAGAGCCCACAAGATTCTT

HMGR real for

Real time

Forward

Exon 2

TGTGGGAACGGTGACACTTA

HMGR real rev

Real time

Reverse

Exon 2

CTTCAAATTTTGGGCACTCA

HCS real for

Real time

Forward

H. Synthase

CTTGGGATGGACGATACGCTTTGG

HCS real rev

Real time

Reverse

H. Synthase

AGGAGCATTTGGCCCAATTAGCAG

18S real for

Real time

Forward

18S RNA

CCATCCAATCGGTAGTAGCG

18S real rev

Real time

Reverse

18S RNA

GTAACCCGTTGAACCCCATT

Table 1. Primer sequences used in experiments. The name of each primer is
included in column one for reference. Column two states the use of the primer.
Column three shows the direction of the primer relative to the template being
amplified. The target of the primers is listed in column four, and the sequence in
column five.
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Growth of Bacteria and Isolation of Plasmid DNA- Plasmids were transformed
into JM109 competent cells (promega) and spread onto LB-Agar plates
containing 100 µg / ml ampicillin. Single colonies were picked for propagation in
larger liquid cultures in Luria-Bertani medium (10 g bactotryptone, 5 g yeast
extract, and 10 g NaCl per liter, pH 7.5) with 100 µg / ml ampicillin. Cultures were
grown overnight with constant shaking. For cell culture work or spotting of
membranes for nuclear run-ons, 500 ml cultures were grown. This plasmid DNA
was isolated by the alkaline lysis method and followed by chromatography using
the QIAGEN Maxi-Prep kit. For in vivo electroporation, 2.5 L cultures were grown.
Plasmid DNA for electroporation was isolated by the same method using the
QIA-Filter GigaPrep kit (QIAGEN). After precipitation, the DNA pellet was
suspended in 400-1000 µl of TE buffer pH 8.0 for the Maxi-Preps, and in an initial
volume of 2 ml for the GigaPreps. The DNA concentrations were then quantified
by measuring the absorbance of a 1:100 dilution of each sample (generally 5 µl
of DNA in 495 µl of water), and multiplying by a factor of 5. The DNA yield varied
depending on the plasmid being propagated. Typical yields were around 0.5-1
mg for the MaxiPreps, and 3-9 mg for the GigaPreps. GigaPrep DNA was diluted
in bacterostatic 0.9 % saline to a final concentration between 1.0 and 2.0 mg / ml,
and passed through a syringe filter to remove undissolved particles. The DNA
was then flash frozen in liquid nitrogen and stored at -20ºC until used. MaxiPrep
DNA was stored at 4ºC. All plasmid preps were confirmed by restriction digestion
and electrophoresis on 1% agarose gels.
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Animals- Male Sprague Dawley rats, 125-150g (Harlan), were allowed free
access to Harlan Teklad 22/5 rodent chow and water. Animals were kept in a
reverse cycle lighting system and were sacrificed at 9:00 to 10:00 am,
corresponding to the third to fourth hour of the dark period when HMG-CoA
reductase expression is at its diurnal high. Animals were rendered diabetic by a
single subcutaneous injection of streptozotocin (Sigma), 65 mg/kg. Diabetes was
verified by the presence of urinary glucose using Clinistix from Bayer. In cases
where animals did not test positive for diabetes, another injection of
streptozotocin was administered. Diabetic animals were typically used 3-5 days
after injection. Where indicated, animals received a subcutaneous injection of 3.0
units/100 g of recombinant human insulin (Novolin 70/30, Novo Nordisk) two
hours prior to sacrifice, unless a different time is indicated in the figure legend.
Some animals were fed ground chow containing 1% cholesterol or 0.02-0.04%
lovastatin for 3 days prior to sacrifice or electroporation. For the electroporation
studies, animals weighed between 175 and 225 g. This size was found to be
optimal for surgical exposure of the liver. Following surgery, animals were kept
on the indicated feeding regimen until time of death. In one experiment, WistarFurth rats were substituted for Sprague Dawley (Figure 21). All procedures were
carried out according to the regulations and oversight of the USF Institutional
Animal Care and Use Committee (IACUC), protocol 2317.

Nuclei Isolation- Nuclei were prepared as previously described by centrifugation
through dense sucrose (92). Briefly, between 2.0 and 2.5 g of rat liver was placed
25

on ice in a beaker containing Nuclei Isolation Buffer- 15 mM Tris-HCl pH 7.5, 15
mM NaCl, 60 mM KCl, 2 mM EDTA, 0.5 mM EGTA, 0.15 mM spermine, 0.5 mM
spermidine, 1.9 M sucrose, 15 mM β-Mercaptoethanol, 0.5 % Triton X-100 and
0.1 mM PMSF. The liver was then minced into small pieces with small scissors
and homogenized in a glass homogenizing vessel with a serrated Teflon pestle
using a drill press. The homogenate was diluted with an equal volume of Nuclei
Isolation Buffer without Triton X-100 and centrifuged at 90,000 x g for 90 minutes
at 4ºC in a Beckman ultracentrifuge with a 50.2Ti rotor. Following centrifugation,
the supernatant was decanted, and the nuclear pellet was resuspended in 1 ml of
cold PBS with 3 mM MgCl2.

Nuclear run-on assay- Nuclear run-on assays were carried out essentially as
previously described (39). After centrifugation, nuclei from 2 g of liver were
resuspended in 1 ml of PBS with 3 mM MgCl2. Next, 100 µl resuspended nuclei
was mixed with 100 µl of 2x run-on buffer (160 mM Tris pH 7.5, 20 mM MgCl2, 2
mg/ml heparin, 1% sarkosyl, 0.7 M ammonium sulfate, 0.8 mM each of ATP,
GTP, UTP) and 250 µCi of α-32P-CTP were added to each reaction. Samples
were incubated at 37ºC to continue extension of RNA transcripts. Samples were
then treated with 50 units DNase I, 40 µg proteinase K, and lysed with the
addition of 50 µl of 10% SDS and 25 µl of 0.2 M EDTA. After extraction and
precipitation, equal counts of 32P-labeled RNA were added to each membraneapproximately 5 x 106 dpm. These membranes were previously spotted with 5 µg
of cDNA encoding HMG-CoA reductase (pRed 227), catalase, or the bluescript
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vector. cDNA probes were described previously (39). Hybridizations were
performed overnight at 57ºC. The next day, membranes were washed with 2x
SSC, 0.1% SDS at room temperature for 1 minute, then 0.2x SSC, 0.1% SDS at
60ºC for 30 minutes, followed by 2x SSC containing 250 µg of RNAse A at 37ºC
for 30 minutes. Membranes were given a quick final rinse in 2x SSC and dried,
followed by exposure to autoradiography film with an enhancing screen at -70ºC
for 1-5 days.

Serum Cholesterol and Glucose - Blood was obtained at the time of sacrifice
by collection in 1.5 ml microcentrifuge tubes. Approximately 1 ml of blood was
centrifuged at >16,000 x g in a bench top microcentrifuge for 2 minutes at room
temperature. The resulting supernatant (serum) was removed and stored at -20
ºC until used. Serum cholesterol levels were determined using the cholesterol
oxidase assay from Pointe Scientific, according to the manufacturer’s instructions.
Serum glucose levels were determined using the glucose oxidase assay kit from
Sigma, according to the protocol provided.

Cell Culture- The H4IIE cell line, was obtained from the American Type Tissue
Collection (ATCC) and grown in Eagle’s modified minimal essential medium
(EMEM) supplemented with 10% fetal bovine serum, 100 U penicillin–
streptomycin per milliliter, and 1 mM sodium pyruvate. Cells were maintained at
37 °C and 5% CO2 in a humidified tissue culture incubator.
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FIGURE 3. Overview of in vivo genomic footprinting- In vivo genomic
footprinting is a powerful technique that is used to examine promoter occupancy
in live cells or tissue. This technique depends on the selective methylation of
exposed guanine residues (and to a lesser extent adenine) in the genomic DNA.
Live cells are treated with dimethyl sulfate (DMS) which readily passes through
the plasma and nuclear membranes. Areas of DNA where protein is bound will
be protected from methylation, while areas of accessible DNA will be methylated.
This effectively takes a “snapshot” of where transcription factors are bound to
promoters at a point in time. Following DMS treatment, high molecular weight
DNA is extracted. Once all the proteins, RNA, and extraneous matter are
removed, the DNA is treated in a reaction with piperidine. Piperidine generates
single stranded nicks in the DNA at methylated guanine residues. This results in
a continuum of different DNA fragments from a population of cells for a given
promoter. In order to examine a particular region of DNA, a promoter-specific
primer is hybridized to the DNA and filled in with a polymerase. The resulting
double stranded fragments receive a piece of linker DNA to be used as a
common end for PCR. These fragments are then amplified in a PCR reaction to
magnify the signal for a particular promoter region. Next the DNA is labeled with
another promoter-specific primer, and run on a sequencing gel. Each site of
methylation and cleavage is represented by an individual band on the gel. DNA
that is extracted first and then treated with DMS (“naked DNA”) is run as a control
(lane 1). In vivo samples will show protections- areas of lightened or missing
bands, indicative of protein binding (lane 2: x, y). Alternatively, significantly
darker bands in the in vivo samples are known as enhancements (lane 3: z).
These areas of enhanced DMS reactivity usually indicate nearby protein binding,
presumably due to bending of the DNA molecule, or possibly the local chromatin
environment affecting the diffusion of the DMS.
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DMS treatment of H4IIE cells- H4IIE cells were plated on 150 mm dishes the
day before the experiment at a density of 3.5 x 106 cells per plate. Four plates
were used per condition. The next day, cells were washed two times with PBS
and switched to serum free media. One group of cells received 100 nM insulin in
the media. Three hours later, media was removed and the cells were incubated
with serum free media containing dimethyl sulfate (10 µl / ml) for 5 minutes. Four
plates were set aside for preparation of naked DNA and did not receive DMS.
Media was removed by aspiration and plates were washed 3 times with PBS.
Each plate then received 1 ml of lysis buffer (100 mM EDTA, 60 mM Tris pH 7.5,
0.1% SDS and 500 µg / ml proteinase K). Cell lysates were transferred to 50 ml
conicals, received additional lysis buffer to a final volume of 10 ml, and were
rocked gently at room temperature for 3 hours.

DMS treatment of rat liver nuclei- Nuclei were prepared by centrifugation
through dense sucrose as described previously from 2 to 2.5 g of rat liver (92).
Following centrifugation, the nuclear pellet was resuspended in 2 ml of Nuclei
Wash Buffer (PBS with 3 mM MgCl2) and transferred to 15 ml conicals. Nuclei
suspensions were then treated with 5 µl of DMS for exactly 30 seconds (Final
concentration of 0.25%). A control sample used for the preparation of naked DNA
was also mock treated without DMS. To stop the methylation reaction,
suspensions were rapidly diluted with 12 ml of cold Nuclei Wash Buffer. Tubes
were then centrifuged at 1,000 g for 5 minutes at 4 ºC to pellet the nuclei. The
supernatant was removed with an aspirator, and the wash was repeated with 3
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ml, and then with 1ml of Nuclei Wash Buffer. The pellets were then resuspended
in 10 ml of a buffer containing 10 mM Tris-HCl pH 8.0, 140 mM NaCl, 10 mM
EDTA, and then transferred to 50 ml conicals. Ten percent SDS was added to
give a final concentration of 0.5%. Proteinase K (100 µl of a 10 mg / ml stock
solution) was also added at this time. Tubes were rocked gently at room
temperature for 3 hours to completely lyse the nuclei.

DMS treatment of rat liver- Rat liver (2.2g) was minced in 8 ml of ice cold PBS.
Liver pieces were homogenized 4-5 times using a drill press with a serrated
Teflon pestle in a glass homogenizing vessel. A 5 ml portion of filtered
homogenate was placed in a 50 ml polypropylene centrifuge tube. Each sample
was then treated with 5 µl of dimethyl sulfate for 2 minutes at room temperature.
The DMS reaction was slowed by rapid dilution with 40 ml of ice cold PBS. Tubes
were centrifuged at 1,000 x g for 5 minutes at 4ºC. Pellets were resuspended in
20 ml of PBS and washed again. The pellet was then resuspended in 15 ml of
lysis buffer (60 mM Tris pH 7.5, 100 mM EDTA, 0.5% SDS and 100 µg/ml
proteinase K). Samples were rocked gently at room temperature for 3 hours to
completely lyse the nuclei.

DNA extraction - Genomic DNA isolation and piperidine treatment were
performed as described previously (93). After lysing nuclei, DNA was extracted
by adding equal volumes of buffered phenol pH 7.5 (Roche), and chloroform:
isoamyl alcohol (24:1). Samples were rocked gently for 10 minutes, and
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centrifuged at 1500 x g to separate the phases. If the aqueous phase was clear,
the supernatant was carefully removed using a cut-off 1000 µl pipetman. Care
was taken to avoid the white interphase. In general, the aqueous phase was
quite viscous due to the presence of very high molecular weight DNA. In
situations where the DNA was cloudy, additional TE Buffer (10 mM Tris-HCl pH,
0.1 mM EDTA) pH 8.0 was added, and the extraction was attempted again. Next,
the aqueous phase was re-extracted with 2 volumes of chloroform: isoamyl
alcohol (24:1) as above. Following extraction, one-tenth volume of 3 M sodium
acetate pH 7.0 was added to the sample and mixed until the sample was clear
and blurry lines were no longer visible. Two and a half volumes of -20ºC 75%
ethanol were gently layered on top of the sample. The DNA was then spooled
using a hooked Pasteur pipet. (Alternatively, if the DNA had no viscosity during
the extractions, it was precipitated with 2.5 volumes of 75% ethanol by incubating
overnight at -20ºC.) DNA was spooled by dipping the curved head of the Pasteur
pipet just below the ethanol layer, and swirling the solution in a circular motion.
The high molecular weight DNA attached to the pipet and had the appearance of
a white silken thread. If a large amount of DNA was recovered, then the DNA
appeared clear and globular. Next, the DNA was washed off the Pasteur pipet
into a 15 ml conical using 1-2 ml of TE buffer and a 1,000 µl pipetman. The final
volume was adjusted with TE Buffer to 3-5 ml if the DNA was spooled, and 1-2
ml if it was precipitated overnight. The next day, the DNA was digested with 100
units of Hind III, a non-cutter for the HMGR promoter, in a minimal volume. The
sample was incubated for 3-4 hours at 37ºC and then extracted as before. After
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the DNA had been spooled a second time, it was gently scraped into a 1.5 ml
microfuge tube using 200 µl of TE buffer. If the DNA was not viscous at this stage,
then it was precipitated overnight and resuspended in 200 µl of TE buffer.

Preparation of control DNA and piperidine treatment- DNA that was extracted
as above, but not DMS treated was used as a control for the footprinting
experiments. This DNA was treated in vitro with DMS as described previously
(93). Briefly, 200 µl of DNA in TE buffer was incubated for 20 seconds with 1 µl of
DMS. The methylation reaction was rapidly stopped by the addition of DMS stop
buffer- 1.5 M sodium acetate pH 7.0, 1.0 M β- mercaptoethanol, and 100 µg
yeast tRNA. (In vivo samples were mock treated with DMS stop buffer and
processed alongside control samples from this step onward.) The sample was
quickly mixed by inversion and immersed in a dry ice ethanol bath for 10 minutes.
The samples were then centrifuged at 16,000 x g for 10 minutes at 4ºC in a
bench top microcentrifuge. The supernatant was removed, and the pellet was
washed with 500 µl of cold 75% ethanol. The pellet was then dried in a speedvac
for 2 minutes. Piperidine was added to the sample to cleave the DNA at
methylated guanines. This was accomplished by diluting piperidine 1:10 in ice
cold water and adding 200 µl to each sample. Samples were then vortexed to
dissolve the pellet and incubated for 30 minutes at 90ºC on a heat block (pellet
often did not fully dissolve). The samples were then frozen in a dry ice / ethanol
bath and lyophilized to dryness in the speedvac. To remove residual piperidine,
the sample was resuspended in 100 µl of distilled water and lyophilized again.
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This was repeated once more with 50 µl of water. After the pellet was dried, it
was resuspended in 50 µl of distilled water. DNA was quantified by measuring
the absorbance of a 1:100 dilution of each sample (generally 5 µl of DNA in 495
µl of water), and multiplying by a factor of 5. Roughly 200-300 µg of DNA was
obtained per sample. DNA was stored at 4ºC until needed for footprinting.

Ligation-Mediated PCR- Ligation-mediated PCR was performed according to
the original method (93). Primers were ordered HPLC-purified from Integrated
DNA Technologies (IDT) at a synthesis scale of 250 nmole. Two sets of primers
were used to examine the occupancy of the HMGR promoter. The first primer set
faces towards the transcription start site and reads “C’s” beginning at -185. The
second primer set faces away from the transcription start site and begins by
reading “G’s” at -58. These primer sets are labeled “Footprinting A-1, A-2, A-3”
and “Footprinting B-1, B-2, B-3” respectively (Table 1). Six to nine micrograms of
DNA containing single stranded breaks were made double-stranded by annealing
a promoter-specific primer (A-1 or B-1, Table 1) and extending with Sequenase
2.0 (USB Corp). To accomplish this, 0.3 pmole of primer was annealed to the
DNA in a 15 µl reaction containing 200 mM Tris pH 7.7, and 250 mM NaCl.
Reactions were incubated in a thermocycler (DNA engine, MJ Research) at 97ºC
for 4 minutes, 58ºC for 30 minutes, and then held at 4ºC. Next 7.5 µl of
Mg/DTT/dNTP solution (20 mM MgCl2, 20 mM DTT, 0.2 mM each dNTP) was
added to the annealed DNA, along with 1.5 µl of Sequenase 2.0 diluted 1:3 in ice
cold TE. The tubes were incubated at 47ºC for 10 min., 60ºC for 5 min., and then
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held at 22ºC. During the 22ºC hold, 6.0 µl of 310 mM Tris-HCl pH 7.7 was added,
and the reaction was stopped by incubation at 67ºC for 10 minutes. In order to
provide a common end for amplification of the HMGR promoter fragments, a
synthetic linker was ligated to the DNA. This linker consisted of two annealed
complementary oligos with a single blunt end (Table1, long linker oligo, short
linker oligo). For the ligation reactions, 20 µl of dilution solution (17.5 mM MgCl2,
42.3 mM DTT, 125 µg / ml BSA) was added to each sample and mixed, followed
by 25 µl of ligation mix (10 mM MgCl2, 20 mM DTT, 50 µg / ml BSA, 50 mM TrisHCl pH 7.7, 3 mM rATP, 100 pmoles of hybridized linker per reaction, and 3 units
of T4 DNA ligase (Promega) per reaction). Ligations were performed overnight at
16ºC in the thermocycler. The next day, ligation reactions were stopped with a 10
minute incubation at 70ºC. Samples then received 8.4 µl of 3 M sodium acetate
pH 7.0, 1.0 µl of yeast tRNA (10 mg / ml), and 220 µl of 95% ethanol, and were
precipitated by a 10 minute incubation at -70 ºC followed by 3 hours at -20 ºC.
Samples were then centrifuged at 16,000 x g for 30 minutes at 4 ºC to pellet the
DNA. The pellet was then washed with 200 µl of 75% ethanol, centrifuged, and
air dried for 10 to 15 minutes. Each sample was then resuspended in 70 µl of
water with occasional vortexing and kept on ice. A 5x Taq buffer was prepared
containing 200 mM NaCl, 50 mM Tris pH 8.9, 25 mM MgCl2, 0.05% (w/v) gelatin.
Next each sample received 29 µl of PCR mix containing 20 µl of 5x Taq buffer,
20 nmole dNTPs, 10 pmole primer 2 (2-A or 2-B, Table 1), 10 pmole long linker
oligo (Table 1) and water to volume. Tubes were mixed by gentle flicking, and 1
µl of AmpliTaq (Applied Biosystems) DNA polymerase was added to each. PCR
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reactions were carried out in a thermocycler at the following temperatures: 97 ºC
2 min.; then 16 cycles of 97 ºC for 1 min., 66 ºC for 2 min., 76 ºC for 3 min.;
followed by 95ºC for 1 min.; 66 ºC for 2 min.; 76 ºC for 10 min. and a hold at 4 ºC.
Prior to beginning the PCR, primer 3 (3-A or 3-B, Table 1) was labeled with γ-32P
ATP in a master mix containing 20 pmole of primer (1 µl of a 1:5 dilution), 2 µl of
10 x Kinase buffer (Promega), 1 µl of water, 15 µl γ-32P ATP (6000 Ci / mM,
Perkin Elmer), and 1 µl of T4 polynucleotide kinase (10 u / µl, Promega) for a
group of five samples using the same primer set. The reaction was incubated at
37 º C for 45 minutes, followed by 68 ºC for 10 minutes. Unincorporated label
was removed with the QIAGEN Nucleotide Removal Kit according to the
manufacturer’s instructions. Labeled primer was eluted in 100 µl of 3 mM Tris pH
8.9 and lyophilized to dryness in a speedvac. The labeled primer was then
resuspended in water (2 µl per reaction) and stored on ice. PCR reactions then
received of 5 µl of Labeling Mix (1 µl of 5 x Taq Buffer, 1.5 µl of 10 mM dNTP mix,
2.0 µl of resuspended labeled primer 3, and 0.5 µl of AmpliTaq) and were labeled
by incubation at the following temperatures: 97 ºC for 3 minutes, 68 ºC for 2
minutes, and 76 ºC for 10 minutes. This cycle was repeated two more times.
Samples then received 296 µl of Taq Stop Buffer (260 mM sodium acetate pH
7.0, 10 mM Tris pH 7.5, 4 mM EDTA, and 10 µg of yeast tRNA per sample) and
were mixed well. DNA was extracted with 800 µl of phenol: chloroform: isoamyl
alcohol pre-mixed at 25:24:1. The aqueous phase was transferred to a new tube
and precipitated overnight at -20 ºC with 1.0 ml of 95 % ethanol. The next day,
samples were centrifuged at 16,000 x g for 30 minutes to pellet the DNA. The
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pellet was washed with 400 µl of 75% ethanol and centrifuged again. After
removing the wash, the pellet was dried in the speedvac (approximately 2-5
minutes) and resuspended in loading dye (80% formamide, 0.5 x TBE, 0.01%
xylene cyanol, 0.01% bromophenol blue) with occasional vortexing. DNA was
heat denatured at 90 ºC for 5 minutes and chilled in ice water. Samples were
loaded onto a 6% denaturing polyacrylamide gel, set up in a 0.4 to 1.2 mm
wedge sequencing apparatus (Gibco S2 sequencing apparatus) and run until the
xylene cyanol front was 4-5 cm from the bottom. The gel was composed of 6%
polyacrylamide (19:1 acrylamide: bis-acrylamide), 7.75 M urea, 1 x TBE) and
was prepared in a 130 ml volume using 1 ml of 10% ammonium persulfate and
36 µl of TEMED. After the run, the gel was transferred to whatman 3 mm filter
paper and dried for 2 hours. The dried gels were allowed to expose
autoradiography film (Kodak Biomax MS Film 35 x 43 cm) with an intensifying
screen (Kodak Biomax Transcreen LE) at -70 ºC for 1 to 7 days, or put on a
Molecular Dynamics Storage Phosphor Screen and developed on a Molecular
Dynamics Storm 860 Phosphorimager. In cases where overall signal intensity
varied greatly between wells, another gel was run with loading adjusted
accordingly.

Identification of protections and enhancements- Clear and legible in vivo
footprints were carefully examined for the presence of protections or
enhancements. The position of the most recognizable protections (▲) and
enhancements (∆) are shown on the side of each figure. It should be noted that
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any given footprint may contain unique protections or enhancements that were
not consistently observed. These are mentioned in the text. Each figure contains
a footprint that is representative for each condition (i.e. normal, diabetic,
cholesterol or lovastatin) in regards to the major sites shown in the insets.

Compilation of in vivo footprinting data- Although several footprints were
obtained for the bottom strand (as in Figure 9), there were not enough legible
footprints to make a fair comparison between the normal and diabetic groups.
The primer set used to reveal the top strand (as in Figure 10) gave the clearest
and most interpretable footprints, with five normal and five diabetic animals per
group. Only bands that varied distinctively from the naked DNA were recorded as
protections or enhancements. These positions were compiled into a spreadsheet
using Microsoft Excel software. Protected areas that were observed in four or
more animals in at least one of the groups were noted in Figure 12. The same
criteria was used to identify enhancements. Therefore the binding sites that are
shown as occupied in figure 12 are all based on footprints from the top strand.

Nuclear extract- Nuclei isolated from 2 g rat liver were resuspended in 1 ml of
PBS containing 3 mM MgCl2, and centrifuged at 3,000 g for 5 minutes at 4°C.
Nuclear pellets were resuspended in 0.5 to 1.0 ml high salt buffer (420 mM NaCl,
20 mM HEPES pH 7.9, 1 mM EDTA, 1 mM EGTA, 20% glycerol, 20 mM NaF, 1
mM Na3VO4, 1 mM Na4P2O7, 1 mM DTT, 0.5 mM PMSF, 1x protease inhibitor
cocktail [Sigma]). Nuclei were lysed by rotating slowly at 4°C for 30 minutes. The
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lysates were then centrifuged at 16,000 g for 15 minutes to pellet nuclear debris.
The supernatant (nuclear extract) was collected and stored at -70°C until needed.
Protein concentrations were determined using the BCA assay (Pierce).

EMSA- Electrophoretic mobility shift assays were performed as previously
described (94). Briefly, probes corresponding to the HMG-CoA reductase
promoter footprinted regions were generated by annealing two complementary
oligonucleotides (IDT). The oligo sequences are given in Table 2. One pmol of
probe was labeled by the Klenow fill in reaction using 20 µCi of γ32P-dCTP, along
with cold 0.125 mM dATP, dGTP, and dTTP. Each probe (25 fmol) was
incubated with 10 µg of rat liver nuclear extract in a binding buffer (10 mM
HEPES pH 7.9, 25 mM KCl, 0.5 mM EDTA, 50 µg/ml poly dI:dC, 5% glycerol, 0.5
mM DTT, 125 µg/ml BSA) for 20 minutes at room temperature. One to two µg of
the following antisera were added to the binding reactions: Sp1 (sc-59x), Sp1
(sc-420x), Egr (sc-110x), CREB-1 (sc-187x), NF-Y (sc-7711x), NF-Y (sc-13045x),
NF-1 (sc-870), from Santa Cruz Biotechnology. Binding reactions were run on a
6% polyacrylamide gel in 0.25x TBE. Gels were dried on 3 mm Whatman paper
and allowed to expose film overnight at -70 ºC.
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Table 2

Probe

Start

End

Top

Bottom

A

-199

-176

CTA GCC ATT GGT TGG CTC GGC CGT

CTG AAC GGC CGA GCC AAC CAA TGG CTA G

B

-170

-147

GAG ATG GTG CGG TGC CCG TTC TCC

CTG AGG AGA ACG GGC ACC GCA CCA TCT C

C

-161

-139

CGG TGC CCG TTC TCC GCC CGG GTG

CTG ACA CCC GGG CGG AGA ACG GGC ACC G

D

-152

-129

TTC TCC GCC CGG GTG CGA GCA GTG

CTG ACA CTG CTC GCA CCC GGG CGG AGA A

E

-142

-119

GGG TGC GAG CAG TGG GCG GTT GTT

CTG AAA CAA CCG CCC ACT GCT CGC ACC C

F

-132

-109

AGT GGG CGG TTG TTA GGG CGA CCG

CTG ACG GTC GCC CTA ACA ACC GCC CAC T

G

-122

-99

TGT TAG GGC GAC CGT TCG TGA CGT

CTG AAC GTC ACG AAC GGT CGC CCT AAC A

H

-112

-88

ACC GTT CGT GAC GTA GGC CGT CAG

CTG ACT GAC GGC CTA CGT CAC GAA CGG T

I

-82

-59

CAG CCT CCC GCC GAT TGG CTA GGG

CTG ACC CTA GCC AAT CGG CGG GAG GCT G

Table 2. DNA oligo sequences used as probes in EMSA experiments. The
probe name is given in the first column. The second and third columns show
which nucleotides in the HMGR promoter that are covered by the probe.
Columns three and four show the nucleotide sequences of the oligos used to
generate the probes.
Transient transfections- H4IIE cells were plated to an initial density of 100,000
cells per well in 24 well plates the day before the experiment. The following day,
the media was removed and the cells were washed one time with PBS. Cells
were transfected with 1 µg of DNA/ well using Promega’s Transfast reagent in
the recommended 2:1 ratio. Cells were co-transfected with reporter construct and
pRL-TK in a 4:1 ratio. One hour after transfection, the 200 µl of transfection mix
in each well was diluted with 800 µl of growth media. 12-16 hours later, cells
were harvested in 100 µl of passive lysis buffer and assayed for luciferase
activity using the Dual Luciferase Assay Kit (Promega). Data are shown as the
average ratio of firefly to Renilla luciferase counts +/- standard deviation of the

39

mean. At least six independent yet identical transfections were performed per
condition. All plasmid concentrations were checked by A260 prior to transfection.

Chromatin preparation from rat liver- Rat liver (2.2 g) was placed in a beaker
containing 10 ml of ice-cold PBS. The liver was minced into small pieces and
diluted with an equal volume of 2% formaldehyde in PBS, followed by a tenminute incubation at room temperature. Formaldehyde cross-linking was stopped
by the addition of 2 ml of 1.25 M glycine. Liver pieces were washed 3 times with
10 ml of ice-cold PBS. Samples were then homogenized in 12 ml of nuclei
isolation buffer + Triton X-100 using a serrated Teflon-glass homogenizer with a
drill press. Nuclei were isolated by centrifugation through dense sucrose
according to protocol. Nuclei were resuspended in 1-2 ml of PBS containing 3
mM MgCl2 and centrifuged at 3,000 g, for 5 minutes in 1.5 ml tubes. The nuclear
pellet occupied about 50 µl volume and was white in color. Nuclei were then
resuspended in 1 ml of nuclei lysis buffer (50 mM Tris pH 8.1, 10 mM EDTA, 1%
SDS, 1µg/ml leupeptin, 1µg/ml aprotinin, and 0.1 µM PMSF). Sonication was
accomplished with a Heat Systems-Ultrasonics W375 sonicater with a microtip.
Ten 10-second bursts at a power setting of 4, 40% duty cycle, were sufficient to
shear chromatin to an average size of 200-600 bp. Shearing of chromatin was
checked by electrophoresis on a 3% agarose gel. Chromatin concentrations were
equalized to 0.3 mg/ml by A260 and stored at -70ºC until needed.
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Chromatin Immunoprecipitation assays- Chromatin immunoprecipitations
were performed essentially as previously described (95). One hundred microliters
of chromatin suspension was diluted with 900 µl of IP dilution buffer (0.01% SDS,
1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl pH 8.1, and 167 mM NaCl)
in a 1.5 ml microcentrifuge tube. Twenty microliters of 10 mg / ml salmon sperm
DNA and 20 µl of 10 mg / ml yeast tRNA were also added to each tube. Samples
were pre-cleared with 80 µl (160 µl of a 50% slurry) of ssDNA/Protein A agarose
beads (Upstate), by rocking for 30 minutes at 4 ºC and then centrifuging for
16,000 g for 5 minutes at 4 ºC. One half of the pre-cleared supernatant was
transferred to a new tube for immunoprecipitation. Each immunoprecipitation
reaction (containing 15 µg of chromatin) received 5 µg of the appropriate
antibody: USF-2 (sc-862), CREB-1 (sc-187x), phospho-CREB (sc7978r). All
antibodies were rabbit polyclonal IgG from Santa Cruz. Tubes were rocked
overnight at 4 ºC to bind antibody to the chromatin. The next day,
immunocomplexes were collected by adding 30 µl (60 µl of slurry) of ssDNA/
Protein A agarose for one hour at 4 ºC. Tubes were then centrifuged at 1,000 g
for 1 minute. The supernatant was removed and saved as the “Input.”
Immunoprecipitations were then washed twice with 1 ml of Wash Buffer A (0.1%
SDS, 1 % Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8.1, 150 mM NaCl),
Wash Buffer B (0.2 % SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH
8.1, 500 mM NaCl), Wash Buffer C (0.25 M LiCl, 1% NP-40, 1% sodium
deoxycholate, 1 mM EDTA, 10 mM Tris-HCl pH 8.1) and then TE Buffer pH 8.0.
Immunocomplexes were eluted by adding IP elution buffer (1% SDS, 0.1 M
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NaHCO3) and shaking on a vortex platform for 15 minutes. Tubes were
centrifuged at 16,000 g for 5 minutes to pellet the beads. The supernatant was
transferred to a new tube. This elution was repeated, and the eluates were
pooled. To reverse the crosslinks, each reaction received 20 µl of 5 M NaCl and
was incubated overnight at 65ºC. The next day, eluates were treated with 10 µl of
0.5 M EDTA, 20 µl of 1 M Tris-HCl pH 6.5, and 2 µl of proteinase K (10 mg / ml)
and incubated at 50ºC for one hour. DNA was extracted with 2 volumes of phenol:
chloroform. The aqueous phase was kept (300 µl) and precipitated with 3
volumes of 95% ethanol for 3 hours to overnight at -20ºC. Tubes were
centrifuged at 16,000 g for 10 minutes to pellet the DNA. The supernatant was
removed and the pellet was washed with 600 µl of 70% ethanol. The pellet was
then dried and resuspended in 30 µl of sterile water. PCR was performed using
primers for the HMG-CoA reductase promoter (82) (ChIP HMGR for, rev) or Exon
12 (ChIP Exon 12 for, rev) of the HMGR gene (Table 1). Fifty microliter PCR
reactions were set up containing 3 µl of immunoprecipitated DNA, 10 pmol of
each primer, 10 pmol each dNTP, 10 µl of 10 x PCR buffer with MgCl2 (Fisher),
and 1.25 units of Taq DNA polymerase (Fisher). Input DNA was diluted 1:100
and used as a positive control in a separate reaction. PCR was carried out in a
thermocycler under the following conditions: 95 ºC for 5 min., 40 cycles of 95 ºC,
58 ºC, 72 ºC, each for 45 seconds, followed by 95 ºC for 1 min., 58 ºC for 2 min.,
72 ºC for 10 min., and held at 4 ºC. Ten microliters of each PCR reaction was run
on a 2.2% agarose gel with ethidium bromide, next to a 100 bp DNA ladder
(Promega).
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In Vivo Electroporation

x

→

Harvest liver
Assay luciferase activity

FIGURE 4. Overview of in vivo electroporation. Rats are anesthetized and
kept under general anesthesia using isofluorane. The liver is then surgically
exposed by making a transverse incision starting from the mid-sagittal position,
approximately 1 cm caudal to the xiphoid process, extending 3 to 4 cm toward
the dorsal surface of the rat. The left, right and median lobes of the liver are
gently pushed out of the incision over a piece of sterile gauze. Plasmid is then
injected beneath the capsular surface of the liver. A circular six node electrode
(0.75 cm diameter) is placed on the liver such that the needle points line the
perimeter of the injection site. A BTX T830 square wave electroporator is used to
administer 6 x 150 ms pulses at 100 V/cm, with a 150 ms rest between pulses.
This electric pulsing temporarily permeabilizes the hepatocytes and also
electrophoretically drives the DNA through. Minor scarring occurs where the
electrode needles are sunk into the liver. This is useful when locating the exact
area of the liver that has been treated. Each animal receives several different
promoter constructs, all at different locations in the liver. Following surgery,
animals have their wounds closed, receive analgesic, and are returned to
standard housing. One day later, the livers are harvested and assayed for
luciferase activity.
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Surgery- Rats were anesthetized with 5% isofluorane in oxygen. The rats were
then fitted with a standard rodent mask and kept under general anesthesia using
3% isofluorane. Next, the surgical site was trimmed with electric clippers and
scrubbed with 70% isopropyl alcohol followed by betadine. The liver was
surgically exposed by making a transverse incision starting from the mid-sagittal
position, approximately 1 cm caudal to the xiphoid process, extending 3 to 4 cm
toward the dorsal surface of the rat. The left, right and median lobes of the liver
were exposed by gently pushing them out of the incision over a piece of sterile
gauze.

Electroporation- Electroporation was performed essentially as previously
described (96). A subcapsular injection of approximately 15 µg of plasmid in 40
µl of sterile saline was performed using a 26 gauge, 3/8 inch length needle. After
injection the plasmid was visible below the capsular surface as a blanched out
area. A circular six node electrode (0.75 cm diameter) was placed on the liver
such that the needle points line the perimeter of the area where the plasmid was
visible. Electrodes were sunk to a controlled depth of 2 mm using a rubber
spacer. After placement of the electrodes, a BTX T830 square wave
electroporator was used to administer 6 x 150 ms pulses at 100 V/cm, with a 150
ms rest between pulses. These settings were found to be optimal for gene
delivery to the liver with minimal tissue damage. Several HMG-CoA reductase
promoter constructs linked to the luciferase reporter gene were tested at different
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locations in the liver. To control for transfection efficiency, a plasmid encoding
renilla luciferase driven by either the thymidine kinase promoter (phRL-TK) or the
CMV promoter (phRL-CMV) was co-administered. Relative to reporter construct,
phRL-TK was mixed in a 1:4 ratio, and phRL-CMV was mixed in a 1:1000 ratio.
These ratios were found to be optimal for detection of firefly and renilla luciferase
at the same luminometer sensitivity. Following electroporation, the liver was
placed back in the abdomen, and the wound was closed with surgical staples. At
the time of surgery, animals were given a single subcutaneous injection of
ketoprofen (5 mg / kg) for analgesia.

Luciferase Assays- Twenty four hours after electroporation, the livers were
harvested and tested for expression of the HMG-CoA reductase constructs by
measuring luciferase activity. Livers were removed from the animal, and the
electroporated region was extracted using a size 3 cork borer (0.6 cm diameter).
Approximately 0.1 to 0.15 g of liver was placed in 600 µl of passive lysis buffer
(Promega) and homogenized using a polytron tissue disruptor. The lysate was
then centrifuged at 16,000 x g for 5 minutes and the supernatant was assayed for
luciferase activity using the dual luciferase assay kit from Promega, and a Turner
Designs 20/20 luminometer.

Treatment of Luciferase Data- For each animal, an untreated area of liver was
assayed for both firefly and renilla luciferase activity. The average firefly and
renilla background counts for all the animals on a given day were subtracted from
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each sample. Any sample with firefly or renilla luciferase counts below
background was excluded. Due to the inherent variability in DNA injection and
electroporation efficiency, all luciferase values were normalized to renilla
luciferase. Renilla luciferase was co-administered in the plasmid mixes using
either phRL-TK (thymidine kinase promoter) or phRL-CMV (CMV promoter).
Similar results were obtained with both renilla luciferase vectors, and expression
of these plasmids did not vary with injection site or feeding regimen. For the
mapping of HMGR promoter activity in normal rats, all animals received phRL-TK
(Figure 20). In the experiment examining the role of the -70/-65 NF-Y site,
animals received phRL-CMV (Figure 21). For the mapping of the sterol response,
three separate experiments were performed. Two experiments were performed
with phRL-TK in which animals were fed 0.02% lovastatin or 1% cholesterol.
These experiments used 3 and 2 animals respectively for each feeding regimen.
Another experiment was performed using phRL-CMV. These animals were fed
either 0.04% lovastatin or 1% cholesterol in the chow for 3 days. Data from these
three experiments were pooled by taking the average ratio obtained for the
shortest promoter construct (-58/+70) of both feeding conditions, and setting this
value to one. Remaining numbers in each experiment were multiplied by a
constant so that the fold response to cholesterol loading or depletion could be
compared for all the different promoter constructs. The resulting pattern of
promoter activity was the same as each of the three individual experiments, and
data from both feeding regimens were treated identically. Calculations were
performed using Microsoft Excel, and Sigma Plot 8.0 software. Pooled data was
46

graphed as the mean ratio of firefly to renilla luciferase +/- standard error of the
mean (Figure 22). P-values were calculated using the student’s t-test.

Isolation of Microsomes- Livers from electroporated animals were used to
prepare microsomes as previously described (27). Approximately one gram of
liver was minced in 10 volumes of ice cold 0.25 M sucrose solution and
homogenized using a drill press with a serrated Teflon pestle in a glass
homogenizing vessel. The homogenate was then centrifuged at 15,000 x g for 15
minutes at 4 ºC. The resulting supernatant was centrifuged at 90,000 x g for one
hour at 4 ºC. After the second centrifugation, the microsomal pellet was
resuspended in 0.25 M sucrose at a concentration of 5-20 mg / ml and stored at 70 ºC. Protein concentrations were determined using the BCA protein assay
(Pierce) according to the manufacturer’s instructions.

Western Blotting- Thirty micrograms of microsomal protein was combined with
at least 3 volumes of Western Sample Buffer (2% SDS, 60 mM Tris pH 6.8, 8 M
Urea, 0.1 M sucrose, 5 % β-Mercaptoethanol, 0.005% bromophenol blue) and
heated to 95-100 ºC for 5 minutes. Samples were cooled on ice for two minutes
and then subjected to SDS-PAGE on 4-15% gradient gels (BioRad). These gels
do not contain SDS. It was found that pre-running these gels for 30 minutes prior
to loading of the sample, resulted in sharper bands and avoided solubility
problems for HMGR. Following electrophoresis, proteins were transferred to a
PVDF membrane, and blocked in 5 % nonfat dry milk with 0.1 % Tween 20 for
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one hour. The membrane was then probed with an antibody to HMG-CoA
reductase - A9 mouse monoclonal from ATCC (30), or β-actin as a loading
control (Sigma catalog A- 5441) for 2 hours to overnight. Anti-mouse horseradish
peroxidase-conjugated secondary antibody from Amersham was used in a
1:5,000 dilution. Membranes were washed 3 x 10 minutes after each antibody
incubation with wash buffer (PBS with 0.1% Tween 20), and developed using
SuperSignal West Pico ECL reagent (Pierce) according to the manufacturer’s
instructions. Each lane represents a sample of liver microsomes from a separate
animal.

RNA Isolation and cDNA synthesis- Total RNA was isolated from 0.4 g of rat
liver using Tri-Reagent (MRC) according to the manufacturer’s instructions.
Ethanol pellets were stored at -70 ºC until the day of the experiment. RNA
concentrations were then determined by measuring the absorbance of a 1:100
diluted sample at 260 nm. Prior to synthesis of cDNA for use in Real-Time PCR,
the isolated RNA was DNase treated using TURBO DNA-Free kit (Ambion).
Some modifications of the published protocol were made (49). Briefly, 23 µg of
RNA was treated using 2 µl of Turbo DNase enzyme in a reaction volume of 30
µl. Next, 5 µg of the isolated and DNase-treated total RNA was used to generate
cDNA for use in Real-Time PCR. The reverse transcriptase reaction was carried
out with the Superscript II First Strand Synthesis system for RT-PCR (Invitrogen)
according to the manufacturer’s instructions.
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Real-Time PCR- Real-Time PCR was conducted according to the protocol from
iQ SYBR green supermix using an iCycler (Bio-Rad) with minor modifications.
The total reaction volume was adjusted to 25 µl down from 50 µl. Two microliters
of cDNA was used as template for reactions with the HMG-CoA reductase
primers (HMGR real for, rev, Table 1), which corresponded to regions of exon 2
(Genbank accession number NM_013134). Reactions to detect HMG-CoA
synthase used two microliters of cDNA with primers that have been described
previously (HCS real for, rev, Table I) (97). Two microliters of a 1:40 dilution of
each cDNA was used for reactions with primers (18S real for, rev, Table 1) to the
rat 18S ribosomal RNA sequences (Genbank accession number X01117). All
primers were used at a final concentration of 100 nM. The annealing
temperature was 61° C, and 40 amplification cycles were performed. Melting
curves were done after each run and a single distinct peak was obtained for each
primer set. The data were processed by iCycler IQ optical system software 3.0
(Bio-Rad) and analyzed by the ∆∆CT method, using Microsoft Excel statistical
programs and SigmaPlot (version 8.0).
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RESULTS

Nuclear run-on assays were performed to determine if insulin acts to
increase transcription of the HMG-CoA reductase gene in the liver. Male
Sprague-Dawley rats were injected with streptozotocin (65 mg/kg) to induce
diabetes. Animals were sacrificed during the third hour of the dark cycle, at the
diurnal high for hepatic HMG-CoA reductase expression. Nuclei were isolated
from the livers of these animals, and nuclear run-on assays were performed as
described in the methods section. Probes for HMGR, Catalase (CAT- a
housekeeping gene) or pBluescript (BLUE- background hybridization) were
spotted onto nylon membranes. Radiolabeled RNA from the nuclear run-on
reactions was then hybridized to these membranes. The signal intensity of each
band is indicative of that gene’s relative rate of transcription. As seen in Figure 5,
panel A, HMGR transcription was greatly diminished in the diabetic animals. It
was also found that administration of insulin to diabetic animals restored HMGCoA reductase transcription to normal in just two hours (Fig. 5, Panel B).
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FIGURE 5. Insulin activates HMG-CoA reductase transcription in diabetic
rats. Nuclei were isolated from normal (N), diabetic (D), or insulin-injected
diabetic rats (I). Extension of RNA transcripts was carried out with α32P- labeled
CTP. Equal dpm of RNA were hybridized to membranes containing 5 µg of cDNA
for HMG-CoA reductase (HMGR), catalase (CAT), or the Bluescript vector (Blue)
A, Nuclear run-ons from two normal (N1 ,N2), and two diabetic rats (D1, D2). B,
Nuclear run-ons from four diabetic rats (D1-4), and four insulin-replenished
diabetic rats (I1-4).
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To determine if the effect of insulin on transcription is related to changes in
serum cholesterol or serum glucose levels, a time course was performed.
Diabetic rats were injected with insulin (3 units / 100 g) and sacrificed 15, 30, 45,
60, or 75 minutes later. Relative HMGR mRNA levels were measured by real
time RT-PCR using 18S ribosomal RNA as an internal control. It was found that
insulin did increase HMGR message levels in a very rapid fashion (Figure 6,
Panel A). It is likely that animal to animal variations in basal HMGR expression
contributed to the scatter in the data. Nonetheless there was a clear correlation
between time after insulin injection and HMGR expression. The effect appeared
to be maximal in as little as 45 minutes. Serum cholesterol levels did not show
any particular trend with time (Figure 6, panel B). Serum glucose however,
showed a time-dependent decrease with insulin treatment, approaching normal
levels only at 75 minutes (Figure 6, panel C). From this experiment it is clear that
insulin rapidly acts to increase HMGR message levels. This effect is not
dependent on changes in serum cholesterol, and precedes the normalization of
serum glucose.
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FIGURE 6. Time course of HMG-CoA reductase mRNA activation by insulin.
Six diabetic rats were injected with insulin and sacrificed at 0, 15, 30, 45, 60 or
75 minutes later. A. HMGR mRNA levels were determined relative to 18S
ribosomal RNA by real time RT-PCR. B. Final serum cholesterol levels were
determined using the cholesterol oxidase assay. C. Final serum glucose was
measured using the glucose oxidase assay.
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These experiments demonstrate that insulin exerts a rapid effect on
HMGR transcription. We hypothesized that this is accomplished by the binding of
an insulin-responsive transcription factor to the promoter to activate transcription.
In order to directly examine the occupancy of the HMGR promoter, we decided to
employ the technique of in vivo genomic footprinting. This method has been used
successfully to map where transcription factors are bound to DNA in vivo (93,98)
(Figure 3). In vivo genomic footprinting allows for a complete and unbiased
survey of the HMGR promoter. Performing this technique in animals ensures that
the footprint reflects physiological regulation of the gene, in the context of the
many nutritional and hormonal stimuli that the liver receives. In order to do this,
we designed a primer set to reveal the bottom strand of the HMGR promoter
which reads cytosines beginning at -185. Another primer set was designed to
reveal the guanines on the top strand beginning at -58. It should be noted that
these primers were designed against the rat HMGR promoter sequence, which
varies slightly (about 10 bp) from the hamster (83). The primer design was based
on PCR and sequencing of the HMGR promoter from the Sprague-Dawley rats
used in our experiments. Minor differences from the published rat sequence
included an extra G at -15 and a reversal of the CG at -3,-4. Numbering is
therefore -1 bp relative to the previously published sequence, based on the
transcription start site (Fig. 2).

Previous work on from our laboratory was performed in H4IIE cells, an
insulin-responsive rat hepatoma line (75). Questions have been raised as to
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whether these cells are an accurate model of HMGR promoter regulation in the
liver. For this reason, we chose to examine the occupancy of the HMGR
promoter first in H4IIE cells, and then compare this to the physiological situation
in the liver. To accomplish this, H4IIE cells were grown in media containing 10%
fetal calf serum and switched to serum free media on the day of the experiment.
One group of cells also received 100 nM insulin. Three hours later, the cells were
treated with DMS and the DNA was prepared as described in the methods. This
DNA was used for ligation-mediated PCR and the resulting labeled products
were run on a sequencing gel (Figure 7). Lane 1 contains naked DNA that was
first extracted and then treated with DMS in vitro. This lane represents all
possible cleavage sites, and the sequence of the promoter can be followed
based upon it. With this primer set, the “C’s” in the sequence can be read as a
result of the reactive guanines on the bottom strand. Lane 2, is an in vivo sample
(-) from the cells treated without insulin, while the sample in lane 3 received
insulin (+). Bands that are absent or reduced in intensity in the in vivo samples,
represent protections where protein binding shields the DNA from dimethyl
sulfate attack. These protections are noted with a filled triangle (▲) in the figures.
Exact nucleotide positions are given at the right.
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FIGURE 7. In vivo footprinting of the HMG-CoA reductase promoter in H4IIE
cells. H4IIE cells were switched to serum free media at time zero, and treated
with (+) or without (-) 100 nM insulin for four hours. Cells were then treated with
dimethyl sulfate and subjected to in vivo genomic footprinting. The first lane
contains “Naked DNA,” or DNA that was first extracted and then treated with
dimethyl sulfate. This represents all possible cleavage sites for this strand of the
promoter. The position of the CRE and the SRE are underlined. The major
protection at -101 of the CRE is shown with a solid triangle (▲).
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There is a strong protection visible at -101 of the CRE, and less obvious
protections at -114 and -71. Despite numerous attempts, the H4IIE cells could
only be footprinted in one direction. It is likely that the other primer set did not
work due to differences from the rat genome sequence. It is interesting that
occupancy of the promoter in H4IIE cells did not vary with insulin treatment. This
agrees with previous observations in the literature. It was found that insulin
treatment did not affect HMGR promoter occupancy in HepG2 cells, despite a
1.5- fold increase in mRNA (89) (HepG2 are an immortalized human hepatoma
cell line). Questions remain about the relevance of insulin regulation of HMGR in
cultured tumor cells, to the physiological situation in the liver. Until now, this
question has not been addressed.

In order to examine the occupancy of the HMGR promoter in rat liver,
nuclei were first isolated from normal or diabetic rats. The nuclei were
resuspended and then treated with DMS. Following this, the DNA was extracted
and subjected to ligation-mediated PCR as before. The footprints obtained from
these samples showed some distinct areas of protection and enhancement
(Figure 8). Protections are noted with a filled triangle (▲). Bands that are
significantly darker in the in nuclei samples, or new bands that appear in these
lanes, are known as enhancements. Enhanced DMS reactivity is indicative of
protein binding in the nearby area, although not necessarily on that particular
residue. Enhancements have been marked with an open triangle (∆). On the
bottom strand (Figure 8, Panel A), there is a very strong protection at -101 of the
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CRE in both normal and diabetic footprints. This was always present and did not
vary with treatment. On the top strand as well, the CRE element is protected in
all cases at -109, -105, -103, and -100 (Figure 8, Panel B). There is also a
particularly striking enhancement at -142 in the diabetic nuclei. This was a
consistent observation for all the diabetic samples and was never observed in
footprints from normal nuclei. It should be noted that the overall signal in the
diabetic samples fades towards the top of the gels (Figure 8, Panel B, lanes 2
and 3). This is indicative of over-treatment with DMS relative to the normal and
control samples. Excessive methylation results in more frequent cleavage of the
DNA, and consequently selects for shorter PCR products. This tends to overrepresent the smaller fragments, and likely explains the presence of lesser
enhancements flanking the CRE seen only in the diabetic samples. Nevertheless,
it is clear that the CRE is occupied in nuclei from both normal and diabetic rats.
In addition there is a very strong enhancement at -142 only in the diabetic
footprints, suggesting that an insulin-responsive factor may act in this area.

58

A.

B.

naked N D1 D3

-71

▲

∆
∆

∆

-87
-95
-101
-106
-114

▲
▲
▲
▲

-126

-109
-105
-100

∆

-137

SRE

-153
-142
-124

CRE

CRE

∆
∆

-165

SRE

-55

N D1 D2 naked

-80

-148
-154

-70

-161

-59

FIGURE 8. Footprinting of the HMG-CoA reductase promoter from rat liver
nuclei. Nuclei isolated from normal (N) or diabetic (D) rats were treated with
dimethyl sulfate to methylate exposed guanine residues. DNA was treated with
piperidine to cleave at these positions, and footprinted by ligation-mediated PCR.
“Naked” refers to DNA that was first purified and then treated with DMS. This
lane represents all reactive guanine residues. Protections are shown with a solid
triangle (▲) and enhancements with an open triangle (∆). The position of the
reactive guanines is shown relative to the transcription start site at the right side
of each gel. The sterol response element (SRE), and cyclic AMP response
element (CRE) are highlighted. A. Footprint for the bottom strand B. Footprint for
top (coding) strand.
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Isolation of nuclei from rat liver takes approximately two hours for a single
animal. It is actually somewhat surprising that protections and enhancements
would still be visible given the long time gap before DMS treatment. Although
there was a striking difference at -142 in the footprints from these nuclei, it was
possible that other important contacts were being missed. In order to get a truer
“in vivo” look at promoter occupancy, it was necessary to have a more rapid
treatment with DMS. In order to accomplish this, livers were removed from the
rats, quickly dounced to disaggregate the hepatocytes, and then immediately
treated with DMS. Overall, the treatment of fresh liver by this method gave more
consistent data, and resulted in the discovery of several important protections
and enhancements that were missed when working with nuclei.

In vivo footprinting was performed on livers from normal or diabetic rats.
On the bottom strand, several areas of DMS protection or enhancement were
detected (Fig. 9). Once more, protections are indicated by a filled triangle (▲),
and enhancements by an open triangle (∆). In both the normal and diabetic
footprints, the CRE was completely protected at -101, and showed enhanced
DMS reactivity at -104, -99 and -95/-94 (Fig. 9, inset). This pattern was seen in
all animals regardless of treatment. A significant protection seen only in normal
animals occurred at -71, as shown in the inset. Other protections, such as those
seen at -137 and -147 were not consistently observed.
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FIGURE 9. In vivo footprint of the hepatic HMGR promoter, bottom strand.
Livers from normal (N), or diabetic (D) rats were treated with dimethyl sulfate to
methylate exposed guanine residues. DNA was footprinted by ligation-mediated
PCR. The “naked” lane shows all reactive guanine residues. Protected bases are
indicated by a solid triangle (▲), while areas of enhanced DMS reactivity are
denoted with an open triangle (∆). Due to weak overall signal, the naked lane
was given a longer exposure to allow for comparison to the in vivo samples. The
-71 region and CRE have been enlarged in the insets.
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On the top strand, the CRE is heavily protected at -100, -105, -103 and 109 (Fig. 10, bottom inset) in both normal and diabetic animals. The A at -102
showed up as an enhancement in both cases. As with the nuclei, a key
difference between the in vivo footprints is a very obvious enhancement at -142
seen only in the diabetic samples (Fig. 10, middle inset). This particularly dark
band, indicating enhanced DMS reactivity, was seen in 4/5 diabetic footprints and
0/5 normal footprints. Conversely, the nearby enhancement at -138 of the normal
lane was not seen in diabetic footprints, suggesting possible competition for a
binding site in this region. Another obvious difference is an enhancement at -161
in the diabetic lane (Fig. 10, top inset). This residue is in the middle of the sterol
response element (SRE) located between -164 and -155. The SRE appears
unoccupied under normal conditions, and enhanced in diabetic samples (4/5
animals). Protections at -189/-190 were seen in all groups, while those at -70
were not observed in the diabetics. Both of these areas contain potential NF-Y
binding sites, with the sequence ATTGG. A partial protection was always visible
at -85 regardless of treatment. In addition, protections at less reactive guanines
such as -121 and -93 were observed whenever the band was detectable in the
naked lane. These also did not vary with treatment.
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FIGURE 10. In vivo footprint of the hepatic HMGR promoter, top strand.
Livers from normal (N), or diabetic (D) rats were treated with dimethyl sulfate to
methylate exposed guanine residues. DNA was footprinted by ligation-mediated
PCR. The“naked” lane shows all reactive guanine residues. Protected bases are
indicated by a solid triangle (▲), while areas of enhanced DMS reactivity are
denoted with an open triangle (∆). The SRE, -142 region, and the CRE have
been enlarged in the insets.
Since there was an enhancement at -161 of the SRE in four of the five
diabetic animals, we wondered if insulin activation could be a result of sterol
regulation through the SRE. It is conceivable that insulin treatment indirectly
activates HMGR transcription by altering liver cholesterol levels. A rapid
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decrease in liver cholesterol, due to conversion to bile acids during feeding,
might result in increased SREBP cleavage, and binding of these factors to the
SRE. To investigate this possibility, we examined livers of rats fed lovastatin or
cholesterol to alter liver cholesterol levels. Animals were fed 0.02% lovastatin or
1% cholesterol for five days (Figure 11). Previous research in our lab has shown
that a similar dose of lovastatin elevates HMGR transcription 4-6 fold (39); while
dietary cholesterol reduces HMGR protein levels to about 1% of control. It should
be noted that dietary cholesterol has only a minor repressive effect on the rate of
HMGR transcription in these animals (99). We predicted that the lovastatin-fed
animals would show strong protections at the SRE, because of elevated
cleavage of SREBPs, induced by sterol deprivation. Curiously, no definitive
protections or enhancements at the SRE were visible when animals were fed
either lovastatin or cholesterol (Fig. 11, inset). The footprints were the same for
the two animals in each group. The CRE was also heavily protected in these
animals, but unchanged by either treatment. The enhancement at -138 seen in
normal animals was also seen in both lovastatin and cholesterol-fed rats. The
enhancement at -142 seen in diabetic rats was noticeably absent from these
animals. In addition, the NF-Y sites at -189/-190 and -70 are readily visible in
this footprint, and protected in both cases. Invariant protections are also visible at
-125, -121 and -85 in this footprint.
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FIGURE 11. In vivo footprinting of the HMGR promoter in rats fed lovastatin
or cholesterol. Rats were fed either 0.02% Lovastatin (L) or 1% cholesterol (Ch)
chow for 5 days. Livers were treated with dimethyl sulfate and footprinted by
ligation-mediated PCR. Protected bases are indicated by a solid triangle (▲),
while areas of enhanced DMS reactivity are denoted with an open triangle (∆).
The SRE (-164/-155) has been enlarged in the inset.
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In vivo footprinting was repeated on the livers of several normal and
diabetic animals. The primer set used to reveal the top strand (as in Figure 10)
gave the clearest and most interpretable footprints, with five normal and five
diabetic animals per group (Figure 12). The data from these footprints was
compared to establish the major areas of difference between normal and diabetic
rats. Protections or enhancements that were observed in four or more animals in
at least one of the groups were noted in Figure 12. In all cases, protections were
observed around -85, as well as -109, -105 and -100 of the CRE. Enhancements
consistently appeared at -102 of the CRE. These were always seen and did not
vary with treatment. There are several noteworthy areas of difference between
the normal and diabetic animals. Four out of five normal in vivo footprints showed
an obvious protection at -70. This protection was never observed in the diabetic
samples (0/5). As with the nuclear footprinting, the enhancement at -142 was
seen only in the diabetic footprints (4/5), and never in the normal (0/5). An
interesting protection at -161 in the SRE coincided with the enhancement at -142,
suggestive of a factor binding between these positions. The enhancement at the
SRE was seen in four of the five diabetic footprints, and never in the normal.
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FIGURE 12. Summary of in vivo DMS reactivity for the hepatic HMG-CoA
reductase promoter. Many areas of DMS protection and enhancement were
observed by in vivo footprinting. The most common and reproducible sites are
noted in this table. Protected bases are indicated by a solid triangle (▲), while
areas of enhanced DMS reactivity are denoted with an open triangle (∆). The
nucleotide position is given relative to the transcription start site. In the next
column, the sequence is given, showing the reactive residue that was detected.
Five normal (N) and five diabetic (D) animals were footprinted. The number of
times each site was affected is expressed as a fraction of the total animals in the
group. Possible factors that may bind are listed in the last column.
In order to identify the major factors bound to footprinted regions, we
performed electrophoretic mobility shift assays (EMSAs). The EMSA is a
straightforward technique used to evaluate in vitro binding of transcription factors
to DNA sequences. A radiolabeled DNA probe is incubated in a binding reaction
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with nuclear proteins and run on a polyacrylamide gel. The free probe will run the
fastest and gives a dark signal at the bottom of the gel. Protein DNA complexes
migrate considerably slower, and are visible as bands closer to the top of the gel.
Addition of antibody can further slow the migration of these complexes, resulting
in a “supershift” up the gel. Short oligonucleotide probes were designed to cover
the major footprinted elements (Table 2, methods section). These probes were
radiolabeled and incubated with nuclear extracts from the livers of normal or
diabetic rats. An invariant band was observed in all lanes about a third of the way
down the gel (Figure 13, marked with a star [*]). This band appeared regardless
of the probe sequence used, and is likely a DNA binding protein that is not
sequence-specific. Aside from this, most of the probes to the footprinted regions
showed distinct binding patterns. This was particularly true for the regions from 152 to -109 (D, E, F), the CRE probe from -112 to -88 (H), and again for the
region from –82 to -59 (I). These regions were selected for characterization of the
factors binding to them (Although visible in this particular gel, probe F did not
consistently show strong binding and was not pursued further).
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FIGURE 13. EMSA analysis of footprinted regions of the HMG-CoA
reductase promoter. Short DNA probes corresponding to the major footprinted
areas were used to detect in vitro protein binding in normal and diabetic rat liver
nuclear extracts. Ten micrograms of nuclear extract from Normal (first lane), or
Diabetic (second lane) rats was incubated with 25 fmol of a 32P-labeled probe
and electrophoresed on 6% polyacrylamide gels. Probes tested were A -199/-176,
B -170/-147, C -161/-134, D -152/-129, E -142/-119, F -132/-109, G -122/-99, H 112/-88, and I -82/-59. The nonspecific band is marked by a star (*).
In an effort to identify the factor binding to the –152/-119 region, we
performed additional EMSAs. Figure 14, Panel A shows an experiment in which
probes to the –152/-129 and -142/-119 regions were incubated in a binding
reaction with normal (N) or diabetic (D) rat liver nuclear extract. This gel confirms
that the same band is present with both probes, albeit with stronger binding to
the -142/-119 region. In an effort to identify this factor, we performed another
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EMSA using nuclear extract from a normal rat (Figure 15, Panel B). Antisera to
either Sp1, Sp3 or Egr-1 were added to the binding reactions. All three of these
proteins are good candidates based on the sequence of the probe. However,
none of these antibodies resulted in a supershift. Once again, the lower band is
nonspecific as seen in figure 13.

Probe:
Antibody:
Nuclear
Extract:

-142/-119

Egr1

Probe: -152/-129 -142/-119
Nuclear
Extract: - N D - N D
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B.
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- N N N N

←?
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FIGURE 14. EMSA analysis of the region from -152 to -119. Short DNA
probes corresponding to the regions from -152 to -129 and from -142 to -119
were used to detect in vitro binding in rat liver nuclear extracts. Ten micrograms
of nuclear extract from Normal (N), or Diabetic (D) rats was incubated with 25
fmol of a 32P-labeled probe and electrophoresed on 6% polyacrylamide gels. The
first lane in each gel (-) is a binding reaction without nuclear extract (probe only).
A. Protein binding to the -152/-129 and the -142/-119 probes in normal or
diabetic rat liver nuclear extracts. B. Protein binding in normal rat liver nuclear
extracts is unaffected by the addition of Sp1, Sp3 or Egr1 antisera. The
nonspecific band is marked by a star (*).
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An experiment was then designed to characterize the sequence specificity
of this unknown protein. This was done by performing an additional EMSA with
cold DNA competitor probes (Figure 15). The first lane contains a binding
reaction with probe only, while the second received ten micrograms of rat liver
nuclear extract from a normal rat. In the third lane, the same unlabeled -142/-119
probe was used in a 10-fold molar excess as a cold competitor. In the remaining
lanes, mutant cold competitor probes were added to the binding reactions. Each
of these competitors harbors a single base pair mutation at a different place in
the sequence. These were added in 10-fold molar excess to the hot probe. The
exact base change substitution is shown above each lane, with the wild type
sequence on top and the mutant sequence on the bottom. The upper band can
be efficiently competed away with wild type competitor (lane 3), and most of the
mutant oligos. Noteworthy exceptions are “C_AG” from –137 to –134, and the
entire sequence “GGGCGGTT” between –129 and –122. The presence of two
binding sites explains why this band is seen as well in the overlapping –152/-129
probe, albeit with weaker signal. The sequence “GGGCGGTT” seems like a good
match for Sp1, whose consensus sequence is “GGGGCGGGGC” with a strong
requirement for the core “GGGCGG”(100). However the inability of Sp1 antisera
to shift this band, suggests that it is actually a different factor with a similar
sequence specificity. In vitro binding ability of this factor did not vary with
diabetes. The nonspecific band seen in other figures (13-16) is visible only in the
lane without competitor (Figure 15, none *). This band is a non-sequence specific
DNA binding protein, as it was effectively competed away in all other lanes.
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FIGURE 15. EMSA analysis of Sp1-like factor binding to the -142/-119
region. A short DNA probe corresponding to the footprinted region between -142
and -119 was used to detect in vitro binding in rat liver nuclear extracts.
Competitor oligos were used in a 10-fold molar excess to the probe where
indicated. The first lane (-) is a binding reaction without nuclear extract. The
second lane (none) is a binding reaction with rat liver nuclear extract but no
competitor. The third lane (w.t.) is a binding reaction with the wild type sequence
used as a competitor. The remaining lanes are labeled with the wild type
promoter sequence on top, and an arrow pointing to the point mutation in the
cold competitor oligo. The nonspecific band is marked by a star (*).
Two areas consistently bound in vivo were the CRE, and the region
surrounding a putative NF-Y site from -70 to -65. In order to identify the factors
responsible for the in vivo footprints in these areas, additional EMSAs were
performed (Figure 16). The probe from -115 to -85, which covers the entire CRE,
showed strong binding with nuclear extracts from both normal and diabetic rats
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(Figure 16). Virtually all of this band could be shifted further up the gel with the
addition of CREB-1 antisera (Figure 16, Panel A), confirming previous
observations (83). Strong binding had also been observed with the probe from 82 to -59. These bands could be shifted with two different antibodies to NF-Y, but
not by an irrelevant antibody (NF-1) (Figure 16, Panel B). This experiment
therefore identifies the footprinted region from -82 to -59, containing the
sequence GATTGG, as an NF-Y binding site, As with the CRE and Sp1-like sites,
in vitro binding to this region did not vary with insulin.
Fig. 16

Antibody:
Nuclear
Extract:

-82/-59
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NF-Y #2
NF-1
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FIGURE 16. EMSA analysis of the CRE and the -70/-65 NF-Y site. Short DNA
probes corresponding to the major footprinted areas were used to detect in vitro
protein binding in normal (N) and diabetic (D) rat liver nuclear extracts. A. Probe
for the CRE (-85/-115) with CREB-1 antisera added where indicated. B. Probe to
the -59/-82 region, with two different NF-Y antisera or NF-1 antisera added as
indicated. The nonspecific band is marked by a star (*).
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Given the strong protection of the CRE seen in all the in vivo footprints,
and the ability of CREB to bind in vitro, we wanted to find out if CREB was in fact
bound in vivo to the hepatic HMGR promoter. To accomplish this, chromatin
immunoprecipitation (ChIP) assays were performed. This method involves
chemically cross-linking proteins to DNA to assay in vivo binding. Once the
chromatin has been cross-linked, it is sheared into small pieces (typically less
than 500 bp in size), and immunoprecipitated with the antibody of interest.
Following immunoprecipitation and extensive washing, the DNA-protein-antibody
complexes are eluted. The DNA is extracted, and PCR is performed to detect the
promoter in question. To see if CREB is bound to the HMGR promoter in vivo,
liver pieces from normal and diabetic rats were cross-linked with formaldehyde.
ChIP was performed and the HMGR promoter was detected by PCR. CREB-1
antibody was able to pull down the HMGR promoter from both normal and
diabetic chromatin (Figure 17, Panel A), while an isotype-matched antibody to an
irrelevant nuclear protein was not (Figure 17, Panel B). This immunoprecipitation
was not able to pull down Exon 12 of the HMGR gene, confirming that DNA was
sheared to an appropriate size. The difference in intensity of the band for CREB
between normal and diabetic samples was not reproducible, although the
promoter was clearly pulled down in both cases. In other experiments the CREB
immunoprecipitation gave a band of equal intensity for both normal and diabetic
chromatin. It should be noted that ChIP analysis by end point PCR is not
quantitative, but merely provides qualitative information about the presence or
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absence of factors on a given promoter. The inability of p-CREB to pull down the
HMGR promoter could be a result of poor antibody-antigen interaction. We would
expect that at least some of the endogenous CREB is phosphorylated.
Regardless, this data confirms reports that CREB is bound to the HMGR
promoter in vivo (101), and validates this observation in the context of the live
animal.
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FIGURE 17. CREB is bound to the HMGR promoter in live animals. Liver
pieces from normal (N) and diabetic (D) rats were cross-linked in 1%
formaldehyde. Nuclei were isolated and lysed. Chromatin was sonicated to an
average size of 200-600 bp. Chromatin 15 µg was immunoprecipitated with no
antibody (beads), an irrelevant antibody (USF-2), CREB-1 antibody, or phosphoCREB antibody. Forty cycles of PCR were performed, and products were run on
a 2.2% agarose gel stained with ethidium bromide. A. PCR to detect the HMGCoA reductase promoter. B. PCR to detect HMG-CoA reductase Exon 12.
75

Another point of interest in the in vivo footprints was the consistent
protection of the NF-Y site identified at –70/-65. Since this site was strongly
protected in 4/5 of the normal footprints, and none of the diabetics, we
hypothesized that this element might play a critical role in activation of
transcription. In order to investigate a possible functional role for this site, we
constructed luciferase reporter plasmids containing the full length HMG-CoA
reductase promoter starting at –325 and ending at +70 of the 5’ untranslated
region. Two identical plasmids harboring mutations in the NF-Y site were also
made. These plasmids were transfected into H4IIE cells. The next day, the cells
were harvested and assayed for luciferase activity (renilla luciferase was cotransfected for normalization purposes). As seen in Figure 18, the wild type
promoter shows a high level of activity relative to the vector backbone. Both of
the mutants significantly inhibited luciferase production, indicating that this NF-Y
site is required for efficient transcription of HMGR.
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FIGURE 18. Effect of mutating the proximal NF-Y site on transcription in
H4IIE cells. A, H4IIE cells were transfected with pGL3 basic, the wild type HMGCoA reductase promoter-luciferase construct (W.T.), or the same plasmid
harboring mutations in the NF-Y site (Mut A, Mut B). For normalization purposes,
each construct was co-transfected with pRL-TK, a plasmid containing the renilla
luciferase gene driven by the thymidine kinase promoter. Relative luciferase units
(R.L.U.) are expressed as the ratio of firefly to renilla luciferase +/- standard
deviation of the mean. B, Schematic of the HMG-CoA reductase promoterluciferase construct in pGL3. C, Sequence of the NF-Y site in the mutant
plasmids from -69 to -65.
These experiments provided invaluable information about the occupancy
of the HMGR promoter, and identified some of the factors that bind to it. In order
to assess the functional relevance of these sites, reporter gene assays were
performed. The rat HMG-CoA reductase promoter was obtained by PCR of rat
genomic DNA. A series of nested deletions of this sequence was cloned in front
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of firefly luciferase. These promoter constructs include a large piece extending
from -770 to +441 relative to the transcription start site, as well as five smaller
pieces from -325, -228, -176, -123, or -58 on the 5’ end to +70 on the 3’ end
(Figure 19). These promoter fragments contain all relevant transcription factor
binding sites previously identified by studies of this promoter in cultured cells.
The major transcription factor binding sites are displayed, as well as their
locations in the reporter constructs (Figure 19, lower panel).

A. -770
B.
C.

+441
-325
-228

D.

-176
-123

E.
F.

-58

+70
++

LRH-1/FTF

NF-Y

SRE Sp1-like CRE

NF-Y

FIGURE 19. Schematic of HMG-CoA reductase promoter- luciferase
constructs. Top panel: Different fragments of the rat HMG-CoA reductase
promoter were obtained by PCR and cloned into the pGL3 vector. The resulting
plasmids encode firefly luciferase driven by the various fragments of the HMGR
promoter: A -770 to + 441, B -325 to +70, C -228 to +70, D -176 to +70, E -123 to
+70 and F -58 to +70. All numbers are given relative to the transcription start site.
Bottom Panel: The location of the major previously identified transcription factor
binding sites: LRH-1/FTF, NF-Y, SRE, Sp1-like, and the CRE.
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Next, we sought to determine the in vivo relevance of these promoter
regions in driving HMGR transcription in the liver. To accomplish this, we used in
vivo electroporation to deliver reporter constructs to the livers of live animals.
This is an established technique for the delivery of plasmid DNA to the liver (96).
This approach has advantages over the other existing methods for introducing
reporter genes into animals. Transgenic mice are expensive and time consuming
to produce, and only one or two reporter genes can be tested at a time, limiting
the effectiveness of this technique (95). Other methods for the introduction of
DNA such as adenoviral infection (102), or hydrodynamic injection primarily
target the liver (103). While these are very effective methods of gene delivery,
they generally require a large number of animals because each animal can
receive only one promoter construct. Using in vivo electroporation, the
expression of reporter genes can be limited to a particular anatomical area of
liver where the plasmid is injected. This allows the testing of multiple promoter
constructs in a single animal. This not only reduces the number of animals
needed for a promoter study, but also helps to control for changes in transgene
expression due to animal to animal variability.

Animals were anesthetized and surgically opened to expose the liver.
Plasmids were then delivered to the liver by subcapsular injection. A six needle
electrode array was used to administer electric pulses and drive the DNA into the
hepatocytes (104,105). Each animal received all six of the promoter constructs in
separate areas of the liver. A plasmid encoding renilla luciferase was co79

administered for normalization of transfection efficiency. Following surgery, the
animals were allowed to eat and recover overnight. The next day, livers were
harvested and assayed for luciferase activity (Figure 20). For each animal, an
area of liver that was not electroporated or injected with DNA was taken as a
control for luciferase background. This is represented by the minus sign in figure
20. The pattern of promoter activity looked essentially the same in an individual
rat (Figure 20, Panel A), as it did for a group of normal rats (Figure 20, Panel B).
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FIGURE 20. Functional mapping of the HMGR promoter in the livers of
normal rats. Normal Sprague-Dawley (175-200 g) rats were electroporated with
the HMGR-luciferase promoter constructs listed in figure 19, along with Renilla
luciferase for normalization. Each animal received all six promoter-luciferase
constructs A-F. A. The pattern of HMGR promoter activity for a single animal.
The minus sign, “-“ indicates an area of liver that was not electroporated but was
assayed for background luciferase activity. B. The pattern of HMGR promoter
activity for a group of six animals. Data is reported as the mean +/- standard error
of the mean for each promoter construct. Statistically significant differences in
promoter activity are noted as follows: p< 0.05 *, p< 0.01 **.
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Although construct A (-770/+441) contains the largest fragment of
genomic sequence, it did not result in more activity than construct B (-325/+70).
This is consistent with previous findings in the literature showing that 277 bp of
the hamster promoter is required for high level expression in vitro (32). When the
promoter construct was shortened from -325 to -228 (comparing B to C), there
was a significant fall-off in activity. This region contains a recently identified LRH1/FTF site, proposed to mediate a repressive effect of bile acids on HMGR
promoter activity (70). Moving from -228 to -176 (Construct C to D) excludes a
previously identified NF-Y site that was constitutively occupied in the footprints.
Deletion of this site had little to no effect on promoter activity in normal rats. The
region from -176 to -123 which contains the SRE and Sp1-like sites, appeared to
have a repressive effect on promoter activity. Construct E, which lacks this region
gave consistently more activity, although this difference did not reach statistical
significance. This is in agreement with in vivo footprinting data which showed that
this region was preferentially occupied in the diabetic state, where transcription is
dramatically reduced (106), suggesting the presence of a transcriptional
repressor. There is a major reduction in promoter activity when comparing
construct E to Construct F. The deleted region contains the CRE (-104 to -96),
and a newly identified NF-Y site (-70 to -65). This fall-off in promoter activity was
highly significant with a p-value of less than 0.01.

The most dramatic difference in promoter activity was observed between
constructs E and F. This region contains both the CRE and the newly identified
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NF-Y site. The CRE was occupied in all the footprints regardless of treatment,
and CRE was the major factor bound in vitro and in vivo. Interestingly, the NF-Y
site at -70 to -65 was bound only in the presence of insulin. This site was found
to be required for efficient transcription in H4IIE cells, as two different mutations
inhibited luciferase production. In order to determine the role of the NF-Y site in
the liver, a similar experiment was performed by in vivo electroporation. WistarFurth rats were electroporated with the wild type construct B (-325 to +70), or two
constructs harboring double point mutations in the ATTGG core of this element.
As shown in figure 21, both mutants resulted in substantially less promoter
activity (mutant B, p < 0.05). This generally agrees with observations in H4IIE
cells (Figure 18) although the relative reduction in activity was not as drastic in
the liver.
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FIGURE 21. Effect of mutating the proximal NF-Y site on HMG-CoA
reductase promoter activity in live animals. Normal Wistar-Furth rats were
electroporated with plasmids containing the HMG-CoA reductase promoter from 325 to +70 along with Renilla luciferase for normalization. Each animal received
an injection of the wild type construct (WT), and an injection of each construct
harboring point mutations in the NF-Y site (A), (B). Data is reported as the mean
+/- standard error of the mean for each promoter construct. There were four
animals in the group. The activity for construct B was significantly lower than the
wild type (p < 0.05).

Considerable effort was made to identify which regions of the promoter
are insulin-responsive in the liver. Experiments were performed with groups of
normal or diabetic rats, as well as diabetic rats replenished with insulin. Despite
numerous attempts, under an array of different experimental conditions, an
insulin response was not observed. In some cases, insulin actually appeared to
repress HMGR promoter activity (data not shown). This may have been due to
glucagon exerting a dominant effect on the relatively short promoter constructs
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through the CRE. It is therefore possible that the true insulin-responsive
element(s) may lie outside of the cloned promoter fragments. Efforts to clone
larger pieces of the promoter extending out to -5 kb were also unsuccessful. PCR
amplicons of genomic DNA were obtained and sequenced, but ligation into the
reporter vector proved impossible. The exact reason for this is unclear, but may
be due to the presence of highly repetitive upstream sequences preventing
selection of positive clones.

The sterol response of the HMGR promoter has been well characterized in
cell culture. It was expected that in the live animal, sterol regulation would also
be mediated through the SRE, although this issue has not been directly
addressed. To accomplish this, male Sprague Dawley rats were fed diets
containing either cholesterol or lovastatin for three days. These two feeding
regimens were intended to cause the greatest possible differences in HMGR
transcription. Cholesterol feeding has been shown to drastically decrease HMGR
protein levels, while having little or no effect on mRNA levels in rats (99).
Conversely, lovastatin feeding is expected to transiently deplete the cell of
cholesterol and mevalonate-derived metabolites, resulting in a compensatory
increase in HMGR expression. This upregulation happens transcriptionally (about
a 4 fold effect) (39), and to a far greater extent, post-transcriptionally (53). The
promoter activity in the cholesterol-fed animals followed a pattern similar to that
observed for normal rats, while the animals fed lovastatin had considerably
greater activity in constructs B, C, and D. Three separate experiments were
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performed, two with 0.02 % lovastatin and 1% cholesterol, and another with
0.04% lovastatin and 1% cholesterol. All three experiments gave the same
pattern for promoter activity and sterol response, although none achieved
significance on their own due to the low number of animals. When the data sets
are combined (Figure 22), a clear picture of sterol regulation emerges.
Constructs B, C, and D, all contain the SRE and would be expected to respond to
lovastatin feeding. These constructs responded 2.8, 2.3, and 2.2-fold to
lovastatin treatment, with p-values of 0.02, 0.04 and 0.04 respectively. Construct
E, which has had the SRE and Sp1-like site deleted, did not respond to lovastatin
(Ratio = 1.3, p=0.44). Unexpectedly, the shortest promoter construct (F) which
extends from -58 to +70 had a significant sterol response (2.6 fold, p= 0.003),
despite low overall activity. This region does not contain any previously identified
response elements.
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FIGURE 22. Response of the HMG-CoA reductase promoter to lovastatin of
cholesterol feeding. Rats were fed either lovastatin (gray bars) or cholesterol
(black bars) for three days. Animals were then electroporated with constructs B-F,
along with Renilla luciferase. Animals were maintained on their respective diets
overnight, and livers were harvested the next day for luciferase measurements.
The data is represented as the mean ratio of firefly to Renilla luciferase +/standard error of the mean. There were a total of 10 animals in each group.

In order to verify that lovastatin and cholesterol actually had an impact on
the expression of endogenous HMGR, we isolated microsomes from the livers of
electroporated animals fed a normal diet, 1% cholesterol, or 0.02 % lovastatin.
These samples were subjected to Western Blotting and probed with antibodies to
HMGR and β-actin. As seen in figure 23, cholesterol drastically reduced HMGR
protein levels, while lovastatin resulted in a remarkable induction of HMGR
protein (Figure 23). This is consistent with previous observations in rats, and
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shows that surgical manipulation of the animal does not adversely affect liverwide expression or regulation of HMGR.

Normal

CH

L

HMGR
Β-Actin

FIGURE 23. Effect of lovastatin or cholesterol feeding on HMG-CoA
reductase immunoreactive protein and mRNA levels. Western blot of HMGCoA reductase in microsomes from rats fed either normal chow (N), 1%
cholesterol (CH), or 0.02% lovastatin (L) for three days. Each lane represents a
separate animal. β-actin was blotted as a loading control.

Since lovastatin and cholesterol can have effects on translation of the
HMGR message, or stability of the protein, measurements of mRNA levels were
also made. Real time RT-PCR was performed on RNA isolated from livers of
electroporated animals. Animals were fed either 1% cholesterol (CH) or 0.04%
lovastatin (L) for 3 days. In agreement with previous nuclear run-on experiments
(39), lovastatin feeding significantly up regulated HMGR mRNA levels greater
than 6-fold (Figure 24, p=6.0 x 10-6).
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FIGURE 24. Effect of lovastatin or cholesterol feeding on HMGR mRNA
levels. Total RNA was isolated from the livers of electroporated animals fed diets
containing 0.04% lovastatin or 1% cholesterol. Relative mRNA levels were
determined by Real time RT-PCR using 18S ribosomal RNA for normalization.
Data is expressed as the mean +/- standard error of the mean for 5 animals per
group.
In the same experiment, real time RT-PCR was performed using primers
to detect the HMG-CoA synthase (HCS) message. HCS is a classic sterolregulated gene with a consensus SRE in its promoter(107). This promoter has
been shown to respond to fluvastatin in CHO cells, and the effect has been
attributed to increased SREBP processing (108). The relative difference in HCS
between the two groups was 6.3 fold, with a p-value of 0.0025 (Figure 25).
Interestingly, HMGR and HCS both showed a nearly identical fold-induction by
lovastatin, suggesting a common mechanism may be responsible for both.
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FIGURE 25. Effect of lovastatin or cholesterol feeding on HMG-CoA
synthase mRNA levels. Total RNA was isolated from the livers of
electroporated animals fed diets containing 0.04% lovastatin or 1% cholesterol.
Relative mRNA levels were determined by Real time RT-PCR using 18S
ribosomal RNA for normalization. Data is expressed as the mean +/- standard
error of the mean for 5 animals per group.
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DISCUSSION
These studies address the regulation of the HMG-CoA reductase
promoter by insulin and sterols in live animals. Here we present the first evidence
that insulin acts to directly increase transcription of the HMG-CoA reductase
gene in rat liver. Diabetic rats have lower rates of HMG-CoA reductase
transcription than normal rats. With only two hours of insulin treatment,
transcription was restored to normal. Previous work from our lab showed that the
corresponding increase in mRNA could be accomplished even in the presence of
cycloheximide (74). Taken together, these results suggest that insulin acts
directly to stimulate the HMG-CoA reductase promoter, and does not require new
protein synthesis.

In vivo footprinting revealed numerous protections and enhancements
throughout the HMGR promoter. The most pronounced of these was at the CRE,
which was occupied under all conditions tested. EMSA analysis confirmed that
CREB-1 present in nuclear extracts from normal or diabetic rat livers could bind
to this element in vitro, in agreement with observations in FRTL-5 cells (83). ChIP
analysis of rat liver confirms the previous finding that CREB is bound to the
HMGR promoter in vivo (82). Given the overwhelming and invariant occupancy of
the CRE in vivo, it seems unlikely that CREB binding is the regulated event in
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insulin activation. This may differ from sterol regulation in CHO cells, in which
SREBP binding has been shown to selectively recruit CREB to the promoter
(101). Although we previously showed that the CRE was required for insulin
activation of this promoter in H4IIE cells (75), in vivo occupancy of this site did
not vary in rat liver. In addition, footprints from H4IIE cells lacked important
protections and enhancements seen in those obtained from liver. Based on this
information, it is clear that insulin regulation in cultured rat hepatoma cells differs
from the physiological regulation of this gene seen in animals.

The enhancement at -138 in normal footprints was not seen in diabetic
samples. Given the GC-rich content of the nearby sequence, it is likely that this
may be due to binding of an Sp1-like factor. In fact, strong in vitro binding activity
was observed with the probe from –142 to –119. The sequence “GGGCGGCTT”
is a close match to the consensus binding sequence for Sp1. Though generally
regarded as a more basal transcription factor, Sp1 has been invoked in the
insulin regulation of several genes, including SREBP-1a (101).

Four of the five diabetic animals showed a particularly striking
enhancement at -142. This enhancement was never seen under the other
conditions examined, including cholesterol and lovastatin treatment. In addition,
only diabetic samples showed a change in the DMS reactivity of the SRE. This
enhancement at -161 of the SRE coincided with the enhancement at -142, and
may be a result of binding of a repressive factor in the -161/-142 region. Binding
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of a factor in this region could distort the DNA in such a way that both -142 and 161 are more susceptible to dimethyl sulfate attack. In addition, this factor may
preclude binding to the Sp1 site downstream of –138. This competition would
explain why enhancements at –138 were only seen in the normal animals (due to
binding at Sp1 sites), and the enhancement at –142 only in the diabetics.

When animals were fed either lovastatin or cholesterol, the footprint
looked essentially identical to that seen in normal animals. This is peculiar
because a similar dose of lovastatin was shown to elevate HMGR transcription 46 fold (39). Three possible reasons for the lack of occupancy at the SRE come to
mind: 1) SREBP binding has been proposed to be a rapid and transient event. It
is known that SREBPs are by themselves weak binders of DNA, suggesting that
nearby factors are needed to stabilize them (82). Therefore SREBPs may not
remain bound to the promoter long enough to show up in the footprints. 2)
Perhaps not all of the cells in the liver respond to lovastatin. It has been
previously shown by immunostaining of livers from rats fed mevinolin (lovastatin),
that detectable HMGR expression is clustered around the blood supply (109).
Uneven distribution of the drug could mean that some cells show a drastic
upregulation of HMGR message, while a larger percentage remain unaffected.
Since in vivo footprinting examines the net promoter occupancy of a population
of all liver cells, the effect could be muted even though mRNA is markedly higher.
3) Lovastatin activation of this gene could occur through another site elsewhere
in the promoter. HMGR is known to have a variant SRE, with lower affinity for
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SREBPs than those found in the LDL receptor and HMG-CoA synthase genes. It
has also been demonstrated that SREBP-1 can bind to the HMGR promoter at
sites other than the SRE (81). In any case, the data strongly suggests that insulin
activation of this promoter occurs by a mechanism distinct from sterol regulation.

The protections at -71 / -70 were not observed in footprints from diabetic
animals. It was found that NF-Y from nuclear extracts could bind to this element.
Curiously, in vitro binding of NF-Y from nuclear extracts did not vary with
diabetes suggesting that other factors may be necessary to stabilize its
interaction with the promoter in vivo. This is the first identification of this proximal
NF-Y site in the HMGR promoter. It is also clear that this site is of particular
functional importance. Mutations to this site substantially decreased overall
transcription in H4IIE cells, as well as in vivo in the liver. The area around -70 is
the classical position for a CCAAT box (110). In this case, the ATTGG sequence
recognized by NF-Y is actually an inverted CAATT box. Given its proximity to the
transcription start site, recruitment of NF-Y is probably a key event in insulin
activation of HMGR.

The areas of protection or enhancement identified in this study generally
correspond with the large protected regions seen previously in DNase I
footprinting studies of the hamster promoter (76). Previous in vivo footprints of
the human promoter in HepG2 cells did not find any differences with insulin
treatment, despite a 1.5 fold increase in mRNA (89). These previous in vivo
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studies also identified the SRE as a protected region, something that was not
observed in rat liver. These reports were useful in both helping us design the
experiments, and in allowing us to compare results from cultured tumor cells to
rat liver. Using the information obtained from these experiments, we can
construct a basic model of promoter occupancy in normal and diabetic rats (Fig.
26). CREB is bound to the promoter at the CRE in both normal and diabetic rats.
The previously described NF-Y site around -189/-190 is occupied in both
situations. Sp1 or a related factor binds in the –142/-119 region, possibly
accounting for the enhancement at -138 in normal rats. This binding is likely
prevented by the presence of a repressive factor that occupies the region
between -142 and -161 in the diabetic animals. The SRE did not have noticeable
protections. The diagram also shows a newly identified NF-Y site at -70/-65 that
is preferentially occupied in the normal animals.
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FIGURE 26. Model of the HMGR promoter in normal and diabetic rat liver.
Schematic of the HMGR promoter showing the major elements that are occupied
in vivo in normal or diabetic rats, along with putative factors bound to those
elements. The nucleotide positions from -200 to -60 are drawn to scale relative to
the transcription start site, and are shown on the ruler at the bottom of the figure.

Through the use of in vivo electroporation, we were able to examine the
function of the footprinted regions in driving HMGR transcription in the liver. In
agreement with previous studies, about 300 bp of upstream sequence was
needed for high level expression. There was no benefit from additional flanking
sequence extending back to -770 or to +441 past the transcription start site. This
is consistent with previous studies in cultured cells (32). In agreement with in vivo
footprinting studies, inclusion of the region from -176 to -123 (contains SRE and
Sp1-like sites) appeared to have a minor repressive effect. This area was
previously found to have protein binding only in situations where the gene was
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not transcriptionally active (106). The CRE and NF-Y sites around -100 and -70
respectively, likely explain the increase in activity seen in construct E. Deletion of
the region from -123 to -58 drastically reduced promoter activity, consistent with
a critical role for CREB and NF-Y in activation of the HMGR gene (82,83,106).

In an effort to map the insulin responsive regions of the HMGR promoter
in the liver, we performed numerous electroporation experiments. Normal and
diabetic rats were electroporated with the HMGR promoter luciferase constructs
shown in Figure 18. In most cases there was no difference in promoter activity
between these groups (data not shown). This was found to be true comparing
diabetic animals to those replenished with insulin. On occasion, insulin actually
appeared to repress promoter activity in the reporter constructs. This does not
agree with HMGR protein or mRNA measurements, Furthermore, nuclear run-on
assays, a direct measure of rates of transcription, showed a clear effect of insulin
(Figure 4). There are at least three likely explanations for this discrepancy: 1) In
vivo electroporation disturbs the hepatocytes in such a way that insulin signal
transduction is negatively affected. This seems reasonable as the insulin
receptor functions as a dimer in the plasma membrane. This would contrast with
sterol regulation that is not dependent on an extracellular signaling cascade. 2)
The HMGR insulin response may require features of the native chromatin
environment which cannot be replicated by a transiently transfected reporter
plasmid. This is a difficult theory to test, but has proven to be the case for other
genes (111). Due to the negative nature of such data, such a problem is probably
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under-reported in the literature. 3) The insulin responsive element(s) lies outside
of the cloned promoter constructs. This seems to be the simplest and most likely
explanation. Changes even at distant binding sites can have a substantial impact
on transcription. This may occur through changes in chromatin structure or
through recruitment of other factors to the promoter. Perhaps recruitment of NF-Y
in particular is an important event.

Another intriguing observation is the loss of HMGR diurnal variation in
PPAR-alpha knockout mice. The diurnal variation correlates well with the major
and minor feeding times for the animals. Most, if not all, of this affect may be
explained by the accompanying changes in insulin levels. Therefore it is
reasonable to hypothesize that PPAR-alpha is in fact required for insulin
regulation of the gene. This is interesting because PPAR-alpha is a ligandactivated nuclear receptor. It is possible that a fatty acid or other metabolite is
released when insulin levels rise. This could then bind to PPAR-alpha and
activate the gene. A similar mechanism has been proposed for insulin regulation
of the SREBP-1 promoter by LXR (112). Indeed, several fatty acids have already
been identified as ligands for PPAR-alpha (113-115). We have searched as far
as 5 kb upstream of the HMGR gene for consensus PPAR-alpha sites, and there
do not appear to be any. It is possible that PPAR-alpha functions through a
variant site, but without more upstream promoter sequence cloned, this cannot
be tested. It is also possible that PPAR-alpha knockout mice lose the diurnal
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variation simply because it is required for the expression of another insulinresponsive factor.
It has also been suggested that bile acids play a role in transcriptional
regulation of HMGR. Administration of an FXR agonist, GW4064 to mice potently
suppresses HMGR mRNA levels in the liver (70). Bile acids bind to the farnesoid
X receptor (FXR). This is a ligand-activated nuclear receptor that affects a
number of important genes in bile acid metabolism. FXR activates small
heterodimeric partner (SHP), by increasing transcription of this gene. SHP is a
non-ligand binding nuclear receptor partner that can pair with other nuclear
receptors to repress transcription, such as the liver receptor homologue-1 /
fetoprotein transcription factor (LRH-1/FTF). It has been proposed that under
conditions of bile acid accumulation, SHP will bind to LRH-1/FTF and prevent its
activation of the HMGR promoter (70). Deletion of the region containing the
alleged LRH-1/FTF site significantly reduced HMGR promoter activity (Figure 20).
However, we saw no change in promoter activity when electroporated animals
were fed either 1% cholic acid (bile acid) or 2% colestipol (bile acid sequesterant)
for three days (data not shown).

The sterol response element is one of the key determinants of HMGR
promoter activity in cultured cells (77). There has been a considerable amount of
work in transgenic mouse models that point to its importance in vivo. For
example, mice overexpressing the mature form of SREBP-2 have drastically
elevated HMGR levels, as well as increased cholesterol synthesis (37). These
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animals rapidly develop fatty livers, showing that when over expressed, SREBP2 can activate the hepatic HMGR promoter. Recent evidence from the liver
specific SCAP knockout mouse points to the importance of SREBPs in
maintaining appropriate levels of HMGR expression (116). These animals lack
SCAP, the accessory protein required for processing of SREBPs to their mature
forms. Thus, SREBPs can not be transported to the Golgi for processing, and
consequently they do not activate target genes. These animals exhibit an 80%
reduction in HMGR expression. In addition, both SREBP-2 and HMGR knockout
mice are embryonic lethal (117,118) - suggesting that the lethal effect of SREBP2 deletion might be ascribed to its inability to activate the HMGR gene during
development. However, until now, the sterol-responsiveness of the HMGR
promoter has not been examined in the context of the liver.

In order to examine sterol regulation of the promoter in the liver, we fed
rats diets containing cholesterol or lovastatin. These diets were intended to
maximize the possible sterol dependent differences in HMGR transcription. It
should be noted that this dose of cholesterol results in little or no change of
HMGR mRNA levels compared to normal chow, despite larger differences in total
liver cholesterol (99). In contrast, lovastatin significantly upregulates transcription
of the HMGR gene (39), in response to the temporary depletion of intracellular
cholesterol (Due to the ensuing compensation by HMGR and LDLR, total liver
cholesterol levels are seldom changed by statin treatment). It is therefore likely
that the difference in promoter activity between the cholesterol and lovastatin-fed
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animals is largely due to activation by lovastatin, rather than repression by
dietary cholesterol. With this in mind, in vivo electroporation showed that all three
constructs containing the HMGR SRE responded to lovastatin. The promoter
construct from -123 to +70 which lacks the SRE did not have a significant
response to lovastatin. This finding is consistent with the predicted 2-3 fold
response to sterol depletion seen for the HMGR promoter in cultured cells (78). It
is unclear why the shortest promoter construct from -58 to +70 responded to
lovastatin, as this promoter construct lacks any of the previously identified
enhancer or sterol response elements. It is worth noting that this construct
extends out to +70, past the transcription start site. This represents the majority
of the 100 bp of 5’ untranslated region present in rat liver HMGR mRNA
(unpublished observations). This sequence contains several predicted hairpin
loops (119) and has been suggested to play a role in translational control of the
gene either by a mevalonate-derived nonsterol product (120), or by dietary
cholesterol (27). The effect of lovastatin or cholesterol feeding on HMGR protein
levels was greater than the observed increase in mRNA levels. This is consistent
with the considerable amount of post-transcriptional regulation of HMGR by
dietary cholesterol. The observed effect of sterol depletion on promoter activity
was less than the 6-fold effect on mRNA seen by real time RT-PCR. There may
be other regulatory elements that help enhance the promoter’s response to sterol
depletion that are not included in our promoter constructs. One such candidate
SRE exists at -820 to -813 with the consensus sequence GTGGGGTG. This
differs from the SRE in the proximal promoter with a single mismatch100

GTGCGGTG. The location of this putative distal SRE calls for further
examination and functional analysis. Alternatively, it is also possible that
lovastatin treatment may have an effect on the stability of the HMGR mRNA.

We demonstrate that the HMGR promoter responds to statin treatment in
the livers of live animals. The exact mechanism responsible for this effect is not
known. Based on other work in the literature, there is at least one likely scenario
that would explain the lovastatin-mediated increase in HMGR transcription.
Lovastatin treatment slows de novo cholesterol synthesis by inhibiting HMGR.
The decrease in cholesterol synthesis transiently reduces intracellular cholesterol
levels. The hepatocytes must then respond by obtaining more cholesterol. This
compensation can occur through increased synthesis, and/or by receptormediated endocytosis (10). To accomplish this, low sterol levels cause SCAP to
dissociate from Insig. The SCAP/SREBP complex is then carried from the ER to
the Golgi for processing. After proteolytic cleavage, the mature SREBPs migrate
to the nucleus to activate target genes (31). HMGR and LDLR are two well
established SREBP target genes (121,122). The nuclear SREBPs then bind to
the HMGR SRE and activate transcription. This is consistent with the fact that the
three largest promoter constructs, all containing the SRE, responded positively to
lovastatin (Figure 22). While largely based on cell culture studies, there is some
supporting in vivo evidence for this model.
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Previous studies in our lab did not detect changes in nuclear SREBP
levels in the livers of rats fed cholesterol or lovastatin (123). However, several
other studies have addressed sterol-dependent processing of SREBPs in the
liver. Hamsters fed a basal diet of 4% colestipol show greater levels of nuclear
SREBP-2 when fed increasing amounts of mevinolin (lovastatin) (124). In
addition, hamsters fed a chow diet with as little as 0.01% cholesterol had
decreased SREBP cleavage and nuclear abundance (125). Mice are also known
to exhibit a statin effect on nuclear SREBP-2 levels in the liver. There was about
a two-fold increase in mice fed 0.2% lovastatin (126). Likewise, fluvastatin has
been shown to increase the mRNA levels of both HMG-CoA reductase and
HMG-CoA synthase in rat liver (108). The effect of fluvastatin on the HMG-CoA
synthase promoter was dependent on the presence of intact SREs and NF-Y
boxes. N-acetyl-leucyl-leucyl-norleucyl (ALLN), a protease inhibitor that prevents
degradation of SREBPs, could also mimic the effect of fluvastatin on the HMGCoA synthase promoter. The authors attributed the fluvastatin effect to increased
SREBP cleavage caused by cholesterol depletion. Since HMGR and HCS mRNA
were elevated to the same degree with statin treatment (Figure 25), it is likely
that the same factor is responsible. It should be noted that while total liver
cholesterol levels do not vary greatly with statin treatment (127), ultimately it is
the intracellular cholesterol in the regulatory pool that makes the difference in
controlling transcription.
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In summary, we have examined the occupancy of the HMGR promoter in
live animals. Diabetes dramatically alters the pattern of transcription factor
binding to the promoter. Both CREB and NF-Y play important roles in the
regulation of the gene. A newly identified NF-Y site at -70/-65, is required for
efficient transcription, and recruitment of this factor to the proximal promoter is
likely a key event in insulin activation. Data suggests that expression of HMGR
plays an important role in determining one’s susceptibility to dietary cholesterol
(128). HMGR expression is severely reduced in diabetic rats, and these animals
have a corresponding loss of cholesterol buffering capacity (129). Likewise,
HMGR may be insulin-regulated in humans based on serum and urinary
mevalonate measurements (73). If insulin-regulation of the gene is compromised,
cholesterol balance could be adversely affected in these individuals. This is of
great relevance to the millions of people who suffer from diabetes today. This
research represents a step forward towards understanding the complex
relationships between diabetes and cardiovascular disease.

Promoter regions responsible for driving HMGR expression in the liver
have been evaluated. We have found that the HMGR promoter can be sterolresponsive in the liver, as it is in cultured cells. The ability to upregulate HMGR in
response to statins may be a factor in determining their cholesterol-lowering
capacity. A recent study has identified polymorphisms in the HMGR gene that
are associated with decreased response to a statin (130). These polymorphisms
were found in intronic regions of the gene, and the mechanism of these effects is
103

not yet known. It will be interesting to see if polymorphisms in the HMGR
promoter, or other genes in the SREBP pathway, will be good predictors of a
person’s response to cholesterol-lowering drugs. We hope that the basic
research presented here will help guide future investigators in discovering more
effective treatments for hypercholesterolemia and cardiovascular disease.
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Appendix: Manipulation of Hepatic HMGR Expression
by Hydrodynamic Tail Vein Injection

INTRODUCTION

HMG-CoA reductase catalyzes the rate limiting step in cholesterol
production. As such it is a critical control point for metabolic regulation. HMGR
expression varies greatly with respect to various dietary and hormonal states.
Dietary cholesterol has a particularly potent ability to reduce HMGR activity and
protein levels. Other factors such as diabetes, thyroid hormone status, age, and
genetic variation all have an influence on the basal expression of HMGR.
Interestingly, hepatic HMGR expression inversely correlates with serum
cholesterol levels in different strains and species of rodents (1). Animals that
express high levels of HMGR are resistant to the serum cholesterol raising action
of dietary cholesterol. Accordingly, animals that express low levels of HMGR, are
particularly susceptible to a dietary cholesterol insult. This holds true for
situations where basal HMGR expression is compromised due to hormonal
deficiencies. Diabetic and hypothyroid rats have markedly diminished expression
of HMGR, and increased sensitivity to dietary cholesterol (2). For example, male
Spargue Dawley diabetic rats may have a basal cholesterol level of 130 mg/dl,
which can be rapidly elevated to 400 mg / dl or more within just a few days of
cholesterol feeding. Normal animals on the same diet will exhibit virtually no
change in serum cholesterol levels. In humans, Type I diabetics have lower rates
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of cholesterol synthesis, and increased cholesterol absorption (3,4). This
underscores the importance of HMGR in cardiovascular disease. It seems
plausible that HMGR expression could play a protective role in guarding against
dietary cholesterol. It has been proposed that HMGR can function as a
“cholesterol buffer” to prevent undesirable increases in serum cholesterol (5). It is
suspected that animals expressing high levels of HMGR can more effectively
downregulate protein levels. This would provide a mechanism for fine tuning
cholesterol synthesis in response to dietary changes. Animals with highest basal
HMGR expression, would have the greatest ability to adjust their synthetic rates.
With the ability to drastically downregulate synthesis, these animals could better
manage the influx of cholesterol from the diet.

It is not known whether HMGR expression is a cause or effect of this
resistance to cholesterol insult. The purpose of this study is to evaluate the role
of HMGR in the maintenance of desirable serum cholesterol levels. To do this,
we have use hydrodynamic tail vein injection to introduce DNA plasmids and
short interfering RNAs to the livers of live mice and rats. The objective was to
artificially manipulate HMGR levels without the constraints of the normal
regulatory mechanisms present in the endogenous gene. If HMGR is a cause of
resistance to dietary cholesterol, then overexpression of HMGR should lend
animals resistant. Conversely, knockdown of HMGR in the liver should lend
animals more susceptible to dietary cholesterol insult.
118

Appendix: (Continued)

METHODS

Animals- Male Balb/cJ mice were obtained from Jackson (figures 1,3). Male
Sprague Dawley rats 50-75 g were ordered from Harlan (Figure 2). Male FVB
(JAX control no. 001800, Figure 4,5,6) and male C57BL/6 mice (JAX control no.
000664, Figure 7,8) were obtained from Jackson labs. The Balb/c AnHSD mice
used in Figures 9 and 10 were from Harlan. All animals except those in figures 1
and 3 were kept on reverse cycle lighting, and sacrificed at 9:00-10:00 am. This
corresponds to the third to fourth hours of the dark cycle, when HMGR
expression is at its diurnal high. All experiments were carried out in accordance
with the regulations of the USF Institutional Animal Care and Use Committee,
protocol numbers 2440, 2976 and 2317.

Plasmids- pRed227 was obtained from ATCC. p5’Luc3,’ a plasmid encoding
firefly luciferase flanked by the rat HMGR 5’ and 3’ untranslated regions was
generated using standard molecular biology techniques. Briefly, rat liver mRNA
was reverse transcribed to make cDNA. This cDNA was used as a template for
PCR to generate the 3’ and 5’ ends of the HMGR message based on the rat
genome reference sequence. These were cloned into pGL3 control (contains an
SV40 promoter) on either side of the luciferase gene. On the 5’ end, Hind III and
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Nco I were used to ligate in the 5’ end. Once this clone was obtained (p5’UTR), it
was digested with Xba I on the 3’ end of the luciferase gene. The HMGR 3’UTR
was then ligated into this site using complementary Nhe I ends. Lindsey Jackson,
cloned the 3’ UTR of HMGR (from +2765 to +4202) to generate the final plasmid.
phRL-CMV was obtained from Promega.

siRNA- siRNA to the firefly luciferase gene has been described previously (6).
siRNA to the rat HMGR 5’ end of the message was designed using the
Whitehead Institute of Biomedical Research at MIT design tool at
http://jura.wi.mit.edu/bioc/siRNAext/home/php. This siRNA was generated by
annealing two complementary oligonucleotides of the sequence 5’AAggacuguguagcuacaaugTT-3’, and 5’-cauuguagcuacacaguccTT-3’ where the
uppercase letters are deoxyribonucleotides, and the lowercase letters are
ribonucleotides. SiRNAs were ordered from IDT as annealed duplexes and later
diluted in sterile saline.

Hydrodynamic tail vein injection- Plasmids were diluted in 0.9% sterile saline
to a volume corresponding to 9% of the body weight of the animal. For example,
a 22 g mouse received plasmid DNA diluted in 1.8 ml of sterile saline. Animals
were restrained using a standard rodent restrainer. To visualize the tail veins,
animals were placed under infrared light for about a minute. The tails were then
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rinsed with 70% alchohol. For mice, the plasmid solution was delivered using a 3
ml syringe equipped with a 27 G needle. For rats, the plasmid solution was
delivered using a 10 ml syringe with a 23 G needle. In every case the plasmid
solution was rapidly injected in 5-10 seconds. Animals that received less than
80% of the injection volume were excluded from the study. Injections for the
animals in figures 1-3 were performed by Dr. Dexi Liu, an expert in the technique
who graciously assisted and trained laboratory personnel.

Other Methods- Microsome preparation, western blotting, and serum cholesterol
determinations were performed as described in the main methods section of the
dissertation. The only exception is Figure 6. For this Western Blot, a large 7.5%
gel was poured using the BioRad Protean II xi gel apparatus. One hundred
micrograms of microsomal protein was loaded in each lane. Following
electrophoresis and transfer, the membrane was cut above 100 KDa, and blotted
for LDL Receptor and HMGR. The LDLR antibody has been described previously
(7), and was used in a 1:5000 dilution.
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RESULTS
This study was undertaken to determine if HMGR expression is a cause or
consequence of resistance to dietary cholesterol. An expression vector for
hamster HMGR, pRed 227 was used in this study. This plasmid encodes a cDNA
for HMG-CoA reductase of about 4.5 kb in size. The vector contains a
constitutively active SV40 promoter that is not subject to regulation by sterols.
The mRNA generated includes a 163 bp 5’ untranslated region, the 2.7 kb coding
sequence, and 1650 bp of the 3’ untranslated region (8). The first task was to
determine if delivery of pRed227 to the liver could result in noticeable HMGR
overexpression. To accomplish this, BALB/c mice were given a hydrodynamic
injection of 40 µg of a control plasmid mix (p5’Luc3,’ phRL-CMV, siRNA to firefly
luciferase) or one to overexpress HMGR (pRed 227, phRL-CMV). Eighteen hours
later, the livers were harvested and western blotting was performed to measure
HMGR protein levels (Figure 1). HMGR was substantially overexpressed in these
two animals (lanes 5 and 6), compared to the control group (lanes 1-4). It should
be noted that these animals were sacrificed near the diurnal low for HMGR
activity, in the first few hours of the light cycle. These mice also received firefly
luciferase (p5’Luc3’) and renilla luciferase for normalization (phRL-CMV). The
first four animals received an siRNA to firefly luciferase and the last two did not.
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As seen in Figure 2, the mice had considerably lower luciferase expression when
the siRNA was co-administered. This shows that hydrodynamic tail vein injection
of siRNAs can effectively silence target genes in the transfected cells.

FIGURE 1. Overexpression of HMGR in Balb/cJ mice by hydrodynamic tail
vein injection. Balb/cJ mice were injected with 40 µg of a plasmid mix containing
either p5’Luc3,’ phRL-CMV (1:500 dilution), and 2 nmol of siRNA against
luciferase (“control”, lanes 1-4) or pRed227 and phRL-CMV (1:500 dilution)
(“pRed 227,” lanes 5 and 6). Microsomes were prepared 18 hours after injection
(during the third to fourth hour of the light cycle). Fifty micrograms of microsomal
protein was subjected to SDS PAGE and Western blotting. Blots were probed
with an antibody to HMGR, and then to β-Actin as a loading control.
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FIGURE 2. Knockdown of luciferase by hydrodynamic tail vein injection.
Livers were harvested from the Balb/cJ mice in figure 1, and assayed for
luciferase activity. The first four animals received an siRNA to firefly luciferase (),
while the last two did not. Relative luciferase units represents the ratio of firefly to
renilla luciferase for each animal.

In the next experiment, small (50-75 g) male Srague Dawley rats were
treated with an siRNA to HMGR by hydrodynamic injection. Eighteen hours later,
the livers were harvested, and microsomes were prepared. HMGR expression
was detected by western blotting. As seen in Figure 3, the two animals receiving
the siRNA had noticeably higher HMGR expression. This result was unexpected,
and may be due to a short term inhibition of HMGR expression causing a
compensatory increase in protein levels.
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FIGURE 3. Compensatory increase in HMGR protein following siRNA
injection. Rats were injected with 40 ug of a plasmid mix containing p5’Luc3,’
phRL-CMV (1:500) (lanes 1 and 2) or these plasmids with 2 nmol of an siRNA
targeting the 5’ end of the HMGR message (lanes 3 and 4). Microsomes were
prepared 18 hours after injection (during the third to fourth hour of the dark cycle).
Fifty micrograms of microsomal protein was subjected to SDS PAGE and
Western blotting. Blots were probed with an antibody to HMGR, and then to βActin as a loading control.
Since HMGR was overexpressed after one day in the Balb/c mice (Figure
1), we decided to see what influence this would have on serum cholesterol levels.
We also wanted to determine what effect overexpression would have on mice fed
a cholesterol rich diet. In previous experiments, feeding FVB and C57BL/6 mice
a diet containing 1% cholesterol for three days did not significantly change serum
cholesterol levels. For this reason, male FVB mice were fed 2% cholesterol and
0.5% cholic acid for three days following the hydrodynamic injection. The cholic
acid is a bile acid intended to increase the rate of cholesterol absorption in the
intestine, as well as decrease clearance of excess cholesterol via conversion to
bile acids. This diet caused a noticeable yellowing of the liver. As seen in Figure
4, mice injected with pRed227 and fed a chow diet (lanes 4-6) overexpressed
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HMGR relative to the uninjected controls (lanes 10 and 11). Interestingly, even
when overexpressed, dietary cholesterol was still able to decrease HMGR
protein levels (lanes 1-3 vs. 7-9). Since pRed227 does not contain a sterolregulated promoter, this must be due to posttranscriptional effects. Serum
cholesterol levels were increased in both the overexpressed and control animals
when fed the cholesterol rich diet (Figure 5). This difference reached statistical
significance with p<0.05 only in the overexpressed mice. Curiously, the animals
receiving pRed227 appeared to have slightly lower serum cholesterol levels than
controls when on a chow diet. This difference did not reach significance, p > 0.05.
It was also found that LDL receptor protein levels were unaffected by the HMGR
overexpression or feeding of dietary cholesterol (Figure 6). This agrees with
previous findings in rats.

FIGURE 4. Overexpression of HMGR in FVB mice by hydrodynamic tail vein
injection after three days. FVB mice were injected with 30 ug of plasmid mix
containing either pRed227 and phRL-CMV (1:500 dilution) (lanes 1-6), or 30 ug
of p5’Luc3,’ and phRL-CMV (1:500 dilution) (lane 7). The remaining control mice
were not injected (lanes 8-11). Mice were then fed 2% cholesterol and 0.5%
cholic acid (lanes 1-3, 7-9) or chow diet (lanes 4-6, 10,11) for 3 days. The livers
were harvested at the third to fourth hour of the dark cycle, and microsomes were
prepared. Sixty micrograms of microsomal protein was subjected to SDS PAGE
and Western blotting using an antibody to HMGR.
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FIGURE 5. The effects of HMGR overexpression on serum cholesterol
levels in FVB mice after three days. Serum was obtained from the mice in the
experiment shown in Figure 4. Serum cholesterol levels were determined using
the cholesterol oxidase assay, by comparison to a standard curve. The gray bars
represent groups of animals fed 2% cholesterol and 0.5% cholic acid. The black
bars represent the animals fed a chow diet. Serum cholesterol is shown as the
average +/- standard error of the mean for 3 animals in each group. The “*”
indicates a statistically significant difference with p < 0.05.
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FIGURE 6. LDL receptor protein levels are unaffected by HMGR
overexpression, or cholesterol and cholic acid feeding in FVB mice.
Microsomes (100 ug of protein) from the FVB mice in the previous experiment
were subjected to Western Blotting using antibodies to LDL Receptor (LDLR), or
HMG-CoA reductase (HMGR). Mice were injected with a plasmid mix containing
30 ug of pRed227 and phRL-CMV (1:500 dilution) (lanes 1-6), or 30 ug of
p5’Luc3,’ and phRL-CMV (1:500 dilution) (lane 7). The remaining control mice
were not injected (lanes 8-12). Mice were then fed 2% cholesterol and 0.5%
cholic acid (lanes 1-3, 7-9) or chow diet (lanes 4-6, 10-12) for 3 days.
Since bile acid flux may be important for the buffering capacity of HMGR,
we decided to remove cholic acid from the diet. C57BL/6 mice were fed diets
containing 2% cholesterol for 5 days following hydrodynamic tail vein injection. At
this point, the livers had a pale yellow color due to the accumulation of
cholesterol in the tissue. Microsomes were prepared, and western blotting was
performed to detect HMGR protein levels (Figure 7). After 5 days, it appears that
expression of pRed227 wanes considerably (lanes 4-6 vs. 10, 11). As seen
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previously, cholesterol feeding was able to completely suppress HMGR protein
levels in the animals receiving pRed227 (lanes 1-3 vs. 7-9). The animals injected
with pRed227 had a significant increase in serum cholesterol levels when fed the
2% cholesterol chow (Figure 8). This was not seen in the control animals. For
unknown reasons, the control animals had higher serum cholesterol levels on a
chow diet than the overexpressed mice.

FIGURE 7. Overexpression of HMGR in c57BL/6 mice five days after
injection. C57BL/6 mice were injected with a plasmid mix containing 20 ug of
pRed227 and phRL-CMV (1:100 dilution) (lanes 1-6), or not injected and left as
controls (lanes 7-11). Animals were fed 2% cholesterol (lanes 1-3, 7-9) or a chow
diet (lanes 4-6, 10 and 11) for five days. The livers were harvested at between
the third and fourth hour of the dark cycle, and microsomes were prepared. Sixty
micrograms microsomal protein was subjected to SDS PAGE and Western
blotting using an antibody to HMGR.
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FIGURE 8. The effects of HMGR overexpression on serum cholesterol
levels in C57BL/6 mice after five days. Serum was obtained from the mice
used in the experiment shown in Figure 7. Serum cholesterol levels were
determined using the cholesterol oxidase assay by comparison to a standard
curve. The gray bars represent groups of animals fed 2% cholesterol. The black
bars represent the animals fed a chow diet. Serum cholesterol is shown as the
average +/- standard error of the mean for 3 animals in each group. The “*”
indicates a statistically significant difference with p < 0.05, “**” indicates p< 0.01.

A similar experiment was also performed using Balb/c mice, since these
gave excellent overexpression after just one day. These Balb/c mice were fed 2
% cholesterol and 0.5% cholic acid for three days following hydrodynamic
injection. As expected there was a considerable yellowing of the livers in these
animals. Western blotting was performed to detect HMGR protein levels (Figure
9). Only one of the mice still had detectable overexpression of HMGR after 3
days (lane 6). As seen before, the cholesterol rich diet was able to completely
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suppress HMGR protein levels in the overexpressed animals, to levels equal to
or lower than the controls (lanes 1-3 vs. 7-9). Both groups of animals had a
modest increase in serum cholesterol levels when fed the cholesterol rich diet
(Figure 10) although these differences did not reach statistical significance. The
animal represented in lane 6 of Figure 9, had final serum cholesterol levels
approximately the same as those in lanes 4 and 5.

FIGURE 9. Overexpression of HMGR in Balb/c mice three days after
injection. Balb/c mice were injected with a plasmid mix containing 50 µg of
pRed227 (lanes 1-6), 50 µg of p5’Luc3’ (lane 10), or not injected and left as
controls (lanes 7-9,11 and12). Animals were fed 2% cholesterol and 0.5% cholic
acid (lanes 1-3, 7-9) or a chow diet (lanes 4-6, 10 and 11) for five days. The
livers were harvested at between the third and fourth hour of the dark cycle, and
microsomes were prepared. Forty micrograms of microsomal protein was
subjected to SDS PAGE and Western blotting using an antibody to HMGR. Dark
and light exposures are shown.
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FIGURE 10. The effects of HMGR overexpression on serum cholesterol
levels in Balb/c mice after three days. Serum was obtained from the Balb/c
mice used in the experiment in figure 9. Serum cholesterol levels were
determined using the cholesterol oxidase assay by comparison to a standard
curve. The gray bars represent groups of animals fed 2% cholesterol and 0.5%
cholic acid. The black bars represent the animals fed a chow diet. Serum
cholesterol is shown as the average +/- standard error of the mean for 3 animals
in each group.
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DISCUSSION

This study sought to determine whether HMGR expression is a cause or
consequence of resistance to dietary cholesterol. We hypothesized that high
HMGR expression lends resistance to dietary cholesterol. This could happen
through a number of possible mechanisms. Three likely scenarios come to mind:
1) High basal HMGR expression results in increased bile acid production, in turn
resulting in a net increase in cholesterol excretion as bile acids. 2) High basal
HMGR expression may affect ABCG5/8 expression. ABCG5 and ABCG8 are
cholesterol transporters in the liver and intestine. Higher expression of these
proteins would help clear free cholesterol from the body. 3) High HMGR
expression could lend a cholesterol buffering capacity to the liver. Animals with
high levels of HMGR would have higher levels of cholesterol synthesis and
depend less on dietary cholesterol. When challenged with a cholesterol-rich diet,
these animals can more effectively downregulate HMGR expression and better
manage the incoming cholesterol.

It is perhaps equally likely that high HMGR expression and the
corresponding resistance to dietary cholesterol is a result of the activity or
expression of some other factor. Animals with low rates of cholesterol absorption
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may inherently express more HMGR than animals with greater rates of
absorption. Likewise, animals with greater rates of cholesterol efflux may also
have higher basal HMGR expression. In both of these situations, a clear
correlation would still exist between high HMGR expression and resistance to
dietary cholesterol insult.

In this work we were able to overexpress HMGR in the liver by
hydrodynamic tail vein injection. The expression was optimal at shorter time
periods (18 hrs), and fell considerably by three days. Five days post injection,
HMGR levels generally returned to normal. Unfortunately, it was very difficult to
realize a significant increase in serum cholesterol levels with short term feeding.
The greatest increase was achieved when FVB mice were fed a diet containing
2% cholesterol and 0.5% cholic acid for 3 days (Figure 5). In this experiment
HMGR protein levels were still overexpressed about 3-fold at time of death
(Figure 4). In terms of serum cholesterol levels, there was no benefit to
overexpressing HMGR in the FVB mice fed a cholesterol rich diet. All other
things being equal, this suggests that high HMGR expression per se, is not
sufficient to lend resistance to dietary cholesterol insult. A similar result was
achieved with the Balb/c mice (Figures 9 and 10) although the final difference in
HMGR expression was not as great. This suggests that high HMGR expression
is not causative, but rather is dependent on some other factor which lends
resistance to dietary cholesterol.
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These factors may be ABCG5 or ABCG8, which have been identified as a
cause of strain specific differences in response to dietary cholesterol (9). There
may be cross talk between the cholesterol absorption pathway and cholesterol
synthesis in the liver. This might occur through cholesterol itself or a metabolite in
the cholesterol biosynthetic pathway that can traverse the bloodstream. Recently
FGF15 has been identified as enterohepatic signal that connects bile acid
absorption in the intestine to bile acid production in the liver (10). This pathway,
or one like it, could modulate HMGR expression in response to changes in
intestinal cholesterol absorption or bile acid efflux.

It is also possible that our system is not ideally suited for testing the role of
HMGR in the maintenance of serum cholesterol levels. A system that would allow
more prolonged or tunable HMGR expression such as adenoviral infection, may
provide more definitive answers to these questions. Likewise, if possible, liver
specific knockdown of HMGR by RNA interference could yield a wealth of
information about the functional relevance of HMGR to whole body cholesterol
balance.
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